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ABSTRACT

Acetate is excreted as a metabolic end product in many microbes. Acetate
production has primarily been studied in bacteria and archaea but is known to occur in
eukaryotic organisms as well. For example, acetate is one of the most abundant
metabolites excreted by the fungal pathogen Cryptococcus neoformans during
cryptococcosis suggesting that acetate production may be important during pathogenesis.
One possible pathway for acetate production in C. neoformans involves the enzymes
xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp), which can generate
acetyl phosphate from either fructose 6-phosphate (F6P) or xylulose 5-phosphate (X5P),
and acetate kinase (Ack), which can then convert acetyl phosphate to acetate. C.
neoformans has an ACK and two XFP open reading frames that we’ve designated as
XFP1 and XFP2, and several studies indicate that these transcripts are expressed and/or
upregulated under infectious conditions. However, until now, the Xfp-Ack pathway in C.
neoformans has not been studied.
Here I describe the first characterization of a eukaryotic Xfp, the C. neoformans
Xfp2. C. neoformans Xfp2 was found to display both substrate cooperativity and
allosteric regulation. C. neoformans Xfp2 showed positive cooperativity in regards to
F6P and X5P binding and negative cooperativity for Pi binding. Activity was inhibited
by ATP, phosphenolpyruvate (PEP), oxaloacetic acid (OAA) and glyoxylate and
activated by AMP. Both PEP and OAA were found to bind at the same or possess
overlapping allosteric sites on the enzyme.
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Prior to this characterization of C. neoformans Xfp2 the only other
phosphoketolases characterized have been from bacteria, and none report the presence of
substrate cooperativity or allosteric regulation. Therefore, Lactobacillus plantarum Xfp
was re-characterized to determine if the enzyme showed substrate cooperativity and/or
allosteric regulation. L. plantarum Xfp displayed negative cooperativity for Pi binding
and was also allosterically inhibited by PEP, OAA and glyoxylate, but activity was
unaffected by the presence of AMP or ATP. Like C. neoformans Xfp2, PEP and OAA
were found to share the same or overlapping allosteric sites on L. plantarum Xfp. This
study proved that substrate cooperativity and allosteric regulation exist for at least some
bacterial Xfps.
Models of C. neoformans Xfp2 monomer and dimer were generated from existing
bacterial Xfp crystal structures. Since bacterial and eukaryotic Xfps may share the
PEP/OAA allosteric site, ligand docking simulations were performed with PEP and OAA
in various proposed binding sites on the C. neoformans Xfp2 model. Site-directed
mutagenesis was performed on residues predicted to hydrogen bond with PEP and OAA
within these sites. However, these studies have yet to reveal the location of the
PEP/OAA allosteric site. More recently the Xfp2 dimer model has revealed new sites
formed between monomers that could serve as the PEP/OAA allosteric site.
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CHAPTER 1

LITERATURE REVIEW OF XYLULOSE 5-PHOSPHATE/ FRUCTOSE 6PHOSPHATE PHOSPHOKETOLASES FROM BACTERIA AND FUNGI

I. INTRODUCTION

Acetate is excreted from the cell as a metabolic end product in many microbes of
the Bacteria, Archaea and Eukarya. Acetate excretion allows for the regeneration of
NAD+ consumed during glycolysis, recycling of coenzyme A (CoASH) required for
generating the central metabolic intermediate acetyl-CoA, and production of ATP under
conditions in which the TCA cycle is not fully operational (1). However, extracellular
acetate dissociates, posing a problem to the cell by acidifying the surrounding
environment, but one way the cell can overcome this problem is by importing
extracellular acetate and utilizing it as a carbon source (2,3). Therefore, cells must
maintain a balance between acetate excretion and utilization. The studies presented in
this dissertation suggest that the regulation of this process is far more complex than
anticipated.
The primary pathways for acetate production in bacteria typically involve the
enzyme acetate kinase (Ack) which converts acetyl phosphate to acetate and energy in
the form of ATP (4). Ack primarily partners with the acetyl phosphate producing
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enzyme phosphotransacetylase (Pta), found in bacteria, one genus of methane producing
archaea, and green algae, which generates acetyl phosphate from excess acetyl-CoA.
Ack can also partner with xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase
(Xfp), which is found in lactic acid bacteria and fungi that generate acetyl phosphate
from pentose phosphate pathway end products xylulose 5-phosphate (X5P) or fructose 6phosphate (F6P) (4). Additionally, both the Pta-Ack and Xfp-Ack pathways provide
mechanisms for controlling cellular concentrations of acetyl-phosphate, which plays an
important role in signal transduction (1). Some bacteria including Escherichia coli have
an acetate forming pyruvate oxidase (PoxB) that generates acetate from pyruvate (1).
Most studies of enzymes involved in acetate production have been in bacteria.
However, acetate is a major metabolic end product in eukaryotic microbes as well, and
many of the enzymes and pathways involved in acetate production in bacteria can be
found in eukaryotic organisms (4-6). This chapter begins with a review of acetate
production in bacteria, archaea, and eukaryotes. Literature describing acetate production
via the Xfp-Ack pathway (which until now had not been studied in eukaryotic microbes)
will be focused on in this chapter and is the central theme throughout this dissertation.
Also, a brief overview will be given on the pathogenic fungus Cryptococcus neoformans
highlighting evidence of the utilization of the Xfp-Ack pathway during cryptococcal
infections.
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II. ACETATE PRODUCTION

Acetate Production in Bacteria
Many studies have focused on the production and utilization of acetate in bacteria.
Bacterial cells perform what is referred to as the “acetate switch” in which cells transition
from a condition of rapid growth, where acetate is excreted, to a period of slow growth
following the depletion of essential carbon sources, where cells begin to scavenge, import
and utilize acetate as a carbon source, allowing growth to continue (1). Acetogenesis, the
excretion of acetate, occurs as a result of the needs to regenerate coenzyme A (CoASH)
for acetyl-CoA production and NAD+ for glycolysis, and it provides a mechanism for
generating ATP under conditions in which the TCA cycle is not fully functioning (1).
The accumulation of both intracellular and extracellular acetate can be toxic to the cell
(2,3). Therefore, it is essential for cells to maintain a proper balance between the benefits
of acetate production and excretion and the uptake and utilization of acetate as a carbon
source when necessary.
E. coli produces acetate aerobically during periods of rapid growth on glucose,
which ultimately inhibits respiration, and anaerobically during mixed-acid fermentation
(1,7). Acetate is produced in E. coli through a pathway involving Pta (EC 2.3.1.8; Eq.
1.1]) and Ack (EC 2.7.2.1; Eq. 1.2) (1,4,8) or by the enzyme pyruvate oxidase (PoxB, EC
1.2.5.1; Eq. 1.3) (1). In the absence of oxygen the Pta-Ack pathway also serves as a
source of ATP when a branched form of the tricarboxylic acid (TCA) cycle is utilized
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that does not generate energy (1). Deletion of the Pta-Ack pathway in E. coli results in
highly reduced acetate production but increased levels of formate and lactate (3) while
deletion of PoxB primarily causes a reduction in biomass and growth efficiency under
aerobic conditions (3,9) . Therefore, the Pta-Ack pathway primarily contributes to
acetate production during anaerobic fermentation while PoxB functions primarily under
aerobic conditions. In addition to redirecting acetyl-CoA overflow and generating ATP
under hypoxic conditions, the Pta-Ack pathway also serves as the primary influence over
intracellular acetyl phosphate concentrations. Acetyl phosphate is a high-energy form of
phosphate that plays important roles in signal transduction (1,10,11). For example, signal
transduction in bacteria often involves a two component signal transduction pathway.
These two component signaling pathways typically involve the phosphorylation of a
histidine kinase that in turn phosphorylates various response regulators resulting in the
activation of the signaling pathway process (12-14). It has been shown that acetyl
phosphate can act as the phosphoryl donor for two component response regulators via
direct phosphoryl transfer (14). Additionally, acetyl phosphate has been found to
regulate other important bacterial processes such as biofilm development (11) and
flagellar expression (15).
acetyl-CoA + Pi ↔ CoA + acetyl phosphate

[Eq. 1.1]

acetyl phosphate + ADP ↔ acetate + ATP

[Eq. 1.2]

pyruvate + ubiquinone + H2O → acetate + ubiquinol + CO2

[Eq. 1.3]
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In addition to Pta, Ack can also partner with Xfp in lactic acid bacteria (16) and
bifidobacteria (17). Xfp generates acetyl phosphate from the pentose phosphate pathway
end products X5P (EC 4.1.2.9; Eq. 1.4) and F6P (EC 4.1.2.22; Eq. 1.5) which can then be
converted to acetate and ATP by Ack (Eq. 1.2) (4,17). The Xfp-Ack pathway will be
discussed in greater detail later on in this chapter. Other enzymes that produce the Ack
substrate acetyl phosphate include glycine reductase (EC 1.21.4.2; Eq. 1.6), and related
enzymes sarcosine reductase (EC 1.21.4.3) and betaine reductase (EC 1.21.4.4),
sulfoacetaldehyde acetyltransferase (Xsc; EC 2.3.3.15; Eq. 1.7), and acetyl phosphate
forming pyruvate oxidase (Pox; EC 1.2.3.3; Eq. 1.8). These enzymes are present in
various bacteria but are not found in E. coli, archaea, or eukaryotes.
xylulose 5-phosphate + Pi → acetyl phosphate + glyceraldehyde 3-phosphate [Eq. 1.4]
fructose 6-phosphate + Pi → acetyl phosphate + erythrose 4-phosphate

[Eq. 1.5]

glycine + Pi + thioredoxin → acetyl phosphate + NH3 + thioredoxin disulfide [Eq. 1.6]
2-sulfoacetaldehyde + Pi → acetyl phosphate + sulfite

[Eq. 1.7]

pyruvate + Pi + O2 → acetyl phosphate + CO2 + H2O2

[Eq. 1.8]

Acetate Production in Archaea
The Pta-Ack pathway is also found in one genera of methane producing archaea,
Methanosarcina, where acetate is utilized to produce methane (18). It has been shown in
Methanosarcina thermophila that Ack and Pta are produced in greater quantities in cells
grown on acetate versus methanol (19,20). Since M. thermophila is a thermophile, the
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Ack and Pta enzymes from this organism have been shown to be active at temperatures
up to 70°C, but activity is greatly reduced at higher temperatures (19,20). Additionally,
gene knockouts of either Ack or Pta in Methanosarcina acetivorans prevents growth on
acetate and carbon monoxide suggesting that both Ack and Pta are essential (21).
Therefore, in Methanosarcina the Pta-Ack pathway primarily acts in the direction of
acetate activation to acetyl-CoA rather than acetate production (22). However, acetate
and formate rather than methane are the primary metabolic end products of M.
acetivorans grown on carbon monoxide suggesting that under this condition the Pta-Ack
pathway acts in the direction of acetate and ATP production (21).
Pyrococcus furiosus, a hyperthermophilic archaeon, has an ADP-forming acetylCoA synthetase (Acd; EC 6.2.1.13; Eq. 1.9) that catalyzes, under physiological
conditions, the reversible conversion of acetyl-CoA to acetate and ATP (23). P. furiosus
can grow at temperatures up to 105°C, and Acd from this organism shows optimal
activity at 90°C. In addition to acetyl-CoA, Acd can also utilize propionyl-CoA (100%)
and butyrl-CoA (92%) as substrates (23). Acd was first described in P. furiosus but has
since been discovered and characterized in some other archaea, including Archaeoglobus
fulgidus (24), Methanococcus jannaschii (24), Haloarcula marismortui (25) and
Pyrobaculum aerophilum (25).
acetyl-CoA + Pi + ADP → acetate + ATP + CoA
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[Eq. 1.9]

Acetate Production in Eukarya
Ack and partner enzymes were originally thought to exist only in bacteria and one
genus of methane-producing archaea, but have more recently been identified in
eukaryotic organisms as well (4,26). The Pta-Ack pathway has been discovered in green
algae and the oomycete Phytophthora (4) but has thus far only been studied in the green
alga Chlamydomonas. Acetate is a major fermentation product of Chlamydomonas
grown under dark, anoxic conditions (27). C. reinhardtii has two Pta-Ack pathways, and
it has been suggested that one may function in the direction of acetate activation while
the other functions in the direction of acetate production (4), though more recent evidence
contradicts this hypothesis (27). Chlamydomonas RNA levels of Ack1, Ack2, Pta1 and
Pta2 are increased following growth in dark, anaerobic conditions suggesting they are
involved in the production of acetate and ATP under these conditions (27). More
recently, it has been discovered that Ack1 and Pta2 are localized to chloroplasts while
Ack2 and Pta1 are localized to the mitochondria (Yang et al. Plant Cell in press). A
reduction of excreted metabolites was observed in all of the double and single mutations
of these enzymes except for an ack2 single mutant suggesting that the C. reinhardtii
chloroplast play the dominant role in acetate production under dark anoxic conditions. A
double mutation of ack1ack2 showed no acetate kinase activity; however acetate was still
produced and excreted under anoxic conditions suggesting the presence of other acetate
producing pathways in this organism (Yang et al., Plant Cell, in press). Additionally,
none of the C. reinhardtii ack/pta knockouts show a growth defect on acetate suggesting
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that neither of the two Pta-Ack pathways contribute to acetate utilization (Yang et al.,
Plant Cell, in press) as previously suggested (4).
Even though ACK open reading frames (ORFs) have been identified in both
euascomycete and basidiomycete fungi, a PTA ORF has yet to be found (4). Instead, all
fungi with a ACK ORF have at least one and in some cases two XFP ORFs suggesting
that Ack partners with Xfp in fungi as in lactic acid bacteria and Bifidobacteria (4).
Additionally, fungi can generate acetate from pyruvate via the pyruvate dehydrogenase
bypass utilizing the enzymes pyruvate decarboxylase (Pdc; EC 4.1.1.1; Eq. 1.10) and
acetaldehyde dehydrogenase (Ald; EC 1.2.1.5; Eq. 1.11) (28,29). A deletion of the
acetaldehyde dehydrogenase genes ALD6 and ALD5 in Saccharomyces cerevisiae
significantly decreases acetate production during anaerobic growth on glucose (29).
Some fungi may also produce acetate using the AMP-forming acetyl-CoA synthetase
(Acs; EC 6.2.1.1: Eq 1.12). In Salmonella enterica Acs activity is regulated through post
translational modification of Lys609. Acetylation of this lysine residue reduced activity
while activation of the acetylated enzyme required deacetylation by CobB, an NAD+
dependent deacetylase of the sirtuin (Sir2) family (30). The same S. enterica Acs lysine
residue is conserved in the fungal Aspergillus nidulans Acs. Analysis of Acs purified
from A. nidulans under both aerobic and anaerobic conditions showed that under
anaerobic conditions Acs had a higher kinetic affinity (Km) for acetate over acetyl-CoA.
Immunoblotting analysis of Acs from A. nidulans grown under anaerobic conditions with
an anti-acetyl-lysine antibody showed it is acetylated on lysine residues, but the identity
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of the acetylated lysine was not reported (31). Therefore, A. nidulans Acs may function
in the direction of acetate production upon acetylation under anaerobic conditions (31)
pyruvate → acetaldehyde + CO2

[Eq. 1.10]

acetaldehyde + NADP+ → acetate + NADPH + H+

[Eq. 1.11]

acetate + ATP + CoA ↔ acetyl-CoA + AMP + PPi

[Eq. 1.12]

Acd, originally identified in thermophilic archaea, which can generate acetate
from acetyl-CoA (Eq. 1.9), has been found in two amitochondriate protists, Giardia
lamblia and Entamoeba histolytica (32). G. lamblia Acd functions primarily in the
direction of acetate formation, and despite utilizing various assays, acetyl-CoA forming
activity has yet to be detected. Enzymatic properties of Acd indicate that it serves as a
primary source of ATP in G. lamblia (32). Native E. histolytica Acd has also been
characterized and found to require the presence of Pi, ADP and a divalent metal cation for
activity. E. histolytica Acd prefers magnesium, iron or manganese for the divalent metal
cation, and is unable to utilize AMP and PPi in place of ADP and Pi (33).
Additional sources of acetate, other than those previously mentioned, have been
identified in some parasitic helminthes (34), protists (34) and algae (35). An
acetate:succinate CoA transferase (Asct; EC 2.8.3.8; Eq. 1.13), identified in some
protists, including Fasciola hepatica, Trichomonas vaginalis, and Trypanosoma brucei,
is responsible for acetate production in mitochondria-like organelles (34). Additionally
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some eukaryotic microbes contain an acyl-CoA hydrolase (Ach; EC 3.1.2.1; Eq. 1.14),
which has been found to be responsible for acetate production in peroxisomes (34,35).
acetyl-CoA + succinate → acetate + succinyl-CoA

[Eq. 1.13]

acetyl-CoA + H2O → acetate + CoA

[Eq. 1.14]

Regulation of Acetate Producing Pathways
In some bacteria it has been shown that the Ack partner enzyme Pta is
allosterically regulated. Allosteric enzymes are regulated by the binding of ligands that
induce a conformational change influencing substrate binding and catalysis (36). There
are two types of Pta enzymes designated as PtaI and PtaII. Only PtaII enzymes exhibit
allosteric regulation. PtaII enzymes consist of two domains while PtaI has only one
domain. Both PtaIs and PtaIIs share homology in their C-terminal domains, which
contains the substrate binding site. The N-terminal domain, present in PtaII but not in
PtaI, is the primary contributor to PtaII allostery (37,38). The allosteric nature of Pta has
primarily been explored in E. coli (37) and S. enterica (38). In the direction of acetyl
phosphate production, E. coli PtaII is inhibited by NADH and ATP and activated by
pyruvate and phosphoenolpyruvate (PEP) (37). In the acetyl phosphate forming direction
S. enterica PtaII is inhibited by NADH and ATP and activated by pyruvate, and studies
suggest that the N-terminal domain serves as a sensor for these two ligands (38). The
intricate regulation of Pta, as demonstrated in Figure 1.1 showing the influences and
effects of S. enterica PtaII regulation as it fits with overall cellular metabolism (38),
suggests that PtaII serves as an important sensor of cellular energy status.
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Most of the characterized Ack enzymes have been shown to follow standard
Michaelis-Menten kinetics; however a few studies suggest the presence of substrate
cooperativity and allosteric regulation (39,40). An older study from 1979 stated that
Bacillus stearothermophilus Ack displayed sigmoidal kinetics for ATP binding in the
direction of acetyl phosphate formation, but this enzyme did not display sigmoidal
kinetics for substrates in the direction of acetate formation (39). Additionally, B.
stearothermophilus Ack activity in the acetyl phosphate forming direction was activated
in the presence of fructose 1,6-bisphosphate (39). Very recently, both Ack enzymes
(designated as AckA1 and AckA2) from Lactococcus lactis were reported to be
allosterically regulated (40). In the direction of acetate formation, both L. lactis AckA1
and AckA2 are inhibited by fructose 1,6-bisphosphate with half maximal inhibitory
concentrations (IC50) of 17 mM and 43 mM, respectively. The cleavage of fructose 1,6bisphosphate that occurs during glycolysis results in the products glyceraldehyde 3phosphate (G3P) and dihydroxyacetone phosphate (DHAP). While DHAP had little
effect on AckA1 and AckA2 activity, G3P inhibited both enzymes, but it inhibited
AckA1 to a greater extent than AckA2. Additionally, the downstream glycolysis
intermediate PEP inhibits both AckA1 and AckA2 with IC50s of 15 mM and 18 mM,
respectively (40). The authors conclude that allosteric control of AckA1 and AckA2 by
major glycolytic intermediates provides a mechanism by which L. lactis can
instantaneously switch between homolactic and mixed acid fermentation depending on
the availability of quickly or slowly metabolized carbohydrate sources (40).
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III. XYLULOSE 5-PHOSPHATE/ FRUCTOSE 6-PHOSPHATE
PHOSPHOKETOLASE (XFP)

Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) is a thiamine
pyrophosphate (TPP)-dependent enzyme that catalyzes the conversion of Pi and xylulose
5-phosphate (X5P) or fructose 6-phosphate (F6P) to acetyl phosphate and glyceraldehyde
3-phosphate (G3P) or erythrose 4-phosphate (E4P), respectively. Xfp functions as a key
enzyme of the phosphoketolase pathway in lactic acid bacteria, shown in Figure 1.2, (41)
and the fructose 6-phosphate shunt in bifidobacteria (17).

Xfp was originally thought to

exist only in bacteria, but XFP ORFs have more recently been identified in euscomycete
and basidiomycete fungi as well (4). Until now only Xfp from bacteria have been
biochemically and kinetically characterized. Native Xfp from Bifidobacterium animalis
(17) along with recombinant Xfp from Lactobacillus plantarum (16), Bifidobacterium
breve (42), Lactococcus lactis (43), Leuconostoc mesenteroides (43) and Pseudomonas
aeruginosa (43) have been purified and characterized. All of these bacterial enzymes
were reported to follow Michaelis-Menten kinetics and were found to possess dual
substrate specificity for both F6P and X5P. Most bacterial Xfps, with the exception of B.
animalis Xfp (17), display higher affinity for the substrate X5P over F6P (16,43) (kinetic
parameters for X5P were not reported for B. breve Xfp).
An Xfp reaction mechanism originally proposed by Yevenes et al. (16) for L.
plantarum Xfp has since been supported by the structure analysis of B. longum Xfp (44).
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Yevenes et al. proposed that Xfp follows a ping pong bi bi kinetic mechanism depicted in
Figure 1.3 (16). In this mechanism, the phosphoketose substrate, in this case X5P, first
interacts with enzyme bound TPP. The TPP-X5P intermediate forms enzyme bound 2α,β-dihydroxyethylidene-TPP (DHETPP) following the dissociation of G3P. DHETPP
undergoes a dehydration reaction to form enzyme bound enolacetyl-TPP which
undergoes ketonization to form enzyme bound 2-acetyl-thiamine pyrophosphate
(AcTPP). Following nucleophilic attack by inorganic phosphate (Pi), acetyl phosphate is
released, and enzyme bound TPP is free to interact with additional substrate.
Interestingly the proposed reaction mechanism suggests that the formation of G3P or E4P
from the substrates X5P or F6P respectively occurs in the absence of Pi.
To date only the structures of the B. breve Xfp (42) and the Bifidobacterium
longum Xfp (44) have been reported. Figure 1.4 shows the dimer (a) and monomer (b)
structures of B. breve Xfp (42). The Xfp structures show that the monomer consists of an
N-terminal (PP domain), middle (PYR domain) and C-terminal domain with the active
site located between the PP and PYR domain, and the minimum functional unit of the
enzyme exists as a dimer. TPP binds within a deep, narrow channel in a V-conformation
leaving the reactive C2 atom exposed to solvent. There are several active site residues
conserved between Xfp and the related TPP dependent enzyme transketolase (TK), an
enzyme of the pentose phosphate pathway that catalyzes the reversible reaction to convert
X5P or ribose 5-phosphate to G3P or sedoheptulose 7-phosphate respectively. One
residue, Glu479, is found in most TPP dependent enzymes and activates TPP through the
formation of a hydrogen bond between the Glu479 side chain and TPP’s N1' atom of
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pyrimidine. Replacement of Glu479 with Ala in B. breve Xfp (42) or Asp in B. longum
Xfp (44) completely abolished activity. Further analysis of conserved B. breve Xfp and
S. cerevisiae TK histidine residues showed that alteration of these residues either severely
reduced or completely abolished activity (Table 1.1) suggesting that at least the initial
Xfp mechanism follows that of other TPP dependent enzymes (42). The Xfp reaction
differs from that of TK primarily by the dehydration of DHETPP and nucleophilic attack
of AcTPP by Pi neither of which occur in the TK reaction. A site is observed in the B.
breve AcTPP intermediate Xfp structure that holds a water molecule believed to be
derived from the dehydration of DHETPP. A similar site is also found in TK, but in TK
this site is located at a greater distance away from the DHETPP intermediate which may
be why dehydration of DHETPP in TK does not occur. Also, it has been proposed that
the C-terminal domain of TK acts as a regulatory domain (45), and this could also be the
case for the C-terminal domain of Xfp. In summary, studies of B. breve and B. longum
Xfp active sites in comparison with the related enzyme TK from S. cerevisiae have
provided important information on how the Xfp reaction proceeds.
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IV. CRYPTOCOCCUS NEOFORMANS

Cryptococcus neoformans, a basidiomycete soil fungal pathogen, is the leading
cause of fungal meningitis worldwide. It was clinically identified as a human pathogen
in 1894. After undergoing several name changes, it was termed its current identification
of C. neoformans around 1950 when many laboratory investigations of this organism
began (46,47). The onset of the AIDS pandemic brought with it a surge of cryptococcal
infections (48,49). The global burden of cryptococcal meningitis in 2006 was estimated
to be around one million cases that resulted in approximately 625,000 deaths, most of
which occurred in sub-Saharan Africa due to the heavy burden of HIV in this area (49).
Cryptococcal meningitis causes more deaths in sub-Sarahan Africa than tuberculosis,
which often receives far greater public attention (Figure 1.5) (49). Current treatments for
cryptococcal infections often involve a combination of amphotericin B and fluconazole
both of which target ergosterol, a component of fungal membranes not present in plants
or animals. However, these drugs can exhibit potentially harmful side effects and
treatment is often long term to prevent the reemergence of infection, especially in HIV
patients (50).
Individuals come into contact with C. neoformans basidospores from
environmental sources such as rotting trees and soil contaminated with bird guano, which
is believed to provide a favorable growth environment for this fungus (48,51). Spores are
inhaled into the lungs where they can cause an immediate infection that is often cleared
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by host immune defenses, or the fungus can enter a dormant state while remaining in the
host. If an individual’s immune system later becomes compromised, the dormant form
can re-emerge and potentially disseminate through the blood stream, cross the bloodbrain barrier, and cause cryptococcal meningitis (Figure 1.6) (51). Originally C.
neoformans was classified into four serotypes designated A, B, C and D, where serotype
A was associated with C. neoformans var. grubii, serotype D was associated with C.
neoformans var. neoformans and serotypes B and C were associated with C. neoformans
var. gatti (47,51). More recently C. neoformans var gatti has been recognized as the
separate species C. gatti (52,53). C. neoformans var. grubii and var. neoformans are
encountered most often in isolates from infected AIDS patients (47,51). Originally
considered less virulent, C. gatti has begun to emerge as a pathogen of even
immunocompetent individuals and was the cause of a recent outbreak of cryptococcal
infections on Vancouver Island in British Columbia, Canada (54). The progression of C.
gatti as a pathogen of immunocompetent individuals is alarming considering it shares
many characteristics known to contribute to pathogenicity in C. neoformans (55).
A number of factors have been identified that aid in C. neoformans’ ability to
combat and overcome host defenses. One factor essential for C. neoformans
pathogenicity is its ability to grow at 37 °C, the temperature encountered during
infection, which is an unusual characteristic for a soil fungus (56). For example,
cryptococcal species Cryptococcus podzolicus, like C. neoformans and C. gatti possess
other virulent attributes such as a protective capsule and melanin production, but it is
incapable of growing at elevated temperatures and, therefore, does not cause infection
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(56,57). C. neoformans is surrounded by a protective polysaccharide capsule that
primarily protects the cell by limiting phagocytosis, the first line of host defense, and
much research has been devoted towards understanding capsule synthesis and
composition as drug targets for cryptococcal infections (58-61). Additionally, C.
neoformans produces and excretes several extracellular enzymes such as laccase,
phospholipase B, and urease that have also been shown to aid in virulence (55). Both
laccase and phospholipase B are localized to the cell wall where laccase mediates
melanin production and phospholipase B has been shown to aid in cell wall integrity (55).
Additionally phospholipase B is secreted outside the cell and has been shown to aid in
extracellular pulmonary dissemination by degrading lung surfactant and phagolysosomal
membranes upon phagocytosis (55,62,63). C. neoformans produces large amounts of
urease that catalyzes the breakdown of urea to ammonia and carbamate which may
enhance central nervous system invasion (55,64,65).
In addition to mechanisms that aid in protection and defense from the hostile host
environment, C. neoformans possesses a surprising tolerance to hostile environments as
well. It has been shown that C. neoformans can reside inside the acidic environment of
the phagolysosome of human macrophages. In fact, treatment of phagolysosomes
containing C. neoformans with chloroquine, which increases lysosomal pH, resulted in
antifungal activity, suggesting that C. neoformans is highly adaptable to acidic pH and
less tolerant to alkaline pH (66). C. neoformans also produces and deposits melanin
within its cell wall which provides a stable population of free radicals that is believed to
confer protection from oxidative killing by macrophages (67). C. neoformans’ ability to
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reside within phagolysosomes has been proposed as a mechanism of crossing the blood
brain barrier in what is termed a Trojan horse dissemination model (47). In support of
the Trojan horse dissemination model, cryptococcal laden monocytes have been found in
the brain suggesting that they can cross the blood brain barrier in this manner (68).
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V. POSSIBLE ROLES OF ACETATE PRODUCING PATHWAYS IN FUNGI

Acetate has been identified as one of the two most abundant metabolites produced
and excreted during cryptococcal infections (5,6); however, the role acetate plays
particularly during infection remains unknown. In addition to the metabolic benefits of
acetate production, such as the generation of ATP and regeneration of coenzyme A, there
is evidence that C. neoformans may excrete acetate as a means of acidifying the
extracellular environment. Alkaline pH has been attributed to the killing of C.
neoformans within macrophages (66,69) suggesting that elevated pH may be harmful to
C. neoformans cells. Additionally, the pH of cryptococcomas has been found to be
between 5.4 and 5.6 in vivo (6) which could be a direct result of excreted acetate.
Several routes for acetate production exist in C. neoformans (Figure 1.7). The
Xfp-Ack (Eq. 1.4, 1.5, and 1.1) pathway has been discovered as a possible source of
acetate in basidiomycete and euscomycete fungi (4). All fungi lack Pta, therefore, Ack is
believed to partner with Xfp as part of a modified pentose phosphate pathway to generate
acetate from pentose phosphate pathway products X5P or F6P. Phylogenetic analysis of
fungal Xfps shows that these sequences separate into two distinct clusters that have been
designated as Xfp1 and Xfp2 (Ann Guggisburg, Tonya Taylor and Kerry Smith,
unpublished data). All fungi that have an Ack have at least one and in some cases, such
as C. neoformans, two Xfp ORFs (4). As with the yeast S. cerevisiae, acetate could be
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produced in C. neoformans from pyruvate through the actions of Pdc (Eq. 1.10) and Ald
(Eq. 1.11) (70).
Evidence for a role of an Xfp-Ack partnership in producing ATP under the
hypoxic conditions encountered in infectious tissue in which oxidative phosphorylation is
limited originates from RNA expression studies. Both C. neoformans Xfp2 and Ack
have been shown to be upregulated under hypoxic conditions typically encountered in
infectious tissue (71). Additionally Xfp2 has been shown to be expressed in C.
neoformans cells collected from the lungs of infected mice; however this same study also
shows elevated expression of Pdc, suggesting that the Pdc-Ald pathway could also be
involved in acetate production under this condition (70). Ack has been found to be
expressed in C. neoformans following macrophage engulfment (72) suggesting that
acetate production and concomitant production of ATP by Ack may be advantageous in
this harsh environment, which includes limiting oxygen and nutrient availability. All of
these studies suggest that an Xfp-Ack partnership may play both an important nutritive
and mechanistic role in controlling surrounding environmental conditions to aid in cell
survival within infectious tissue.
Currently there have been no studies on the physiological role of Xfp in C.
neoformans; however, a few studies provide some evidence of its role in other fungi. An
Xfp2 homolog in the insect fungal pathogen Metarhizium anisopliae is required for full
virulence (73), providing the first physiological evidence that Xfp2 may be important
during fungal infections. The filamentous fungus Aspergillus nidulans has an Xfp1 and
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Ack but no Xfp2. Overexpression of Xfp1 in A. nidulans resulted in increased specific
growth rate on xylose, glycerol and ethanol but had no effect on growth on glucose (74).
Therefore, Xfp1 was attributed to providing greater carbon metabolism flexibility in A.
nidulans for growth on non-optimal carbon sources. The fission yeast
Schizosaccharomyces pombe is the only yeast identified to have an Xfp, belonging to the
Xfp1 family with no Ack, providing evidence of additional functions for Xfp besides
acting as an Ack partner enzyme. Microarray studies have indicated increased Xfp RNA
levels in S. pombe following exposure to environmental stresses such as oxidative stress
due to hydrogen peroxide, heavy metal stress by cadmium sulfate, heat shock stress,
osmotic stress by sorbitol, and alkylating stress (75). Additionally, a S. pombe Xfp
mutant was capable of growing on rich YES (yeast extract-sucrose) medium containing
glucose between 29 – 32 °C, however, the ability of this mutant to grow under stressful
conditions has not been reported (76,77). As studies continue to shed light on the
physiological role of acetate production and possible roles of Xfp1, Xfp2, and Ack in
fungi, biochemical knowledge is lacking in regards to the function of any of these
enzymes in eukaryotic organisms.
In addition to the production of acetate, the transport and utilization of acetate as
an alternative carbon source is important during C. neoformans infection as well. The
acetate transporter Ady2 along with the enzyme acetyl-CoA synthetase (Acs) have both
been shown to be upregulated in C. neoformans cells collected from the lungs of infected
mice (70), suggesting that C. neoformans takes up acetate and uses Acs to convert it to
the central metabolic intermediate acetyl-CoA. Deletion of C. neoformans Acs results in
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poor growth on acetate, ethanol and glycerol (Figure 1.8a). Also, Acs deletion mutants
demonstrate attenuated virulence in a mouse inhalation model (Figure 1.8b) (70).
Additionally, enzymes of the glyoxylate cycle, malate synthetase and isocitrate lyase, are
also upregulated during infection (70,78). The primary role of the glyoxylate cycle is to
produce energy from simple two carbon molecules such as acetate and ethanol when
glucose availability is limiting. Further studies showed that C. neoformans isocitrate
lyase deletion mutants were unable to grow on acetate as a sole carbon source yet
demonstrated no defect in animal virulence models or a defect in growth within the
macrophage. Therefore, even though glyoxylate cycle enzymes are upregulated during
infection, these enzymes are not required for continued pathogenesis (78).
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TABLE 1.1 Kinetic parameters for B. breve Xfp wild type and variants (Ref 42).
(Permission granted for the reuse of this table)
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FIG 1.1 S. enterica PtaII function and regulation
regulation.. This figure depicts the regulation
of PtaII by various metabolites and how PtaII fits into cellular energy metabolism in S.
enterica. Dashed
ed lines with an arrow indicate a positive effect on PtaII activity while
dashed lines with a blunt end indicate a negative effect. S. enterica PtaII is activated by
pyruvate and inhibited
nhibited by ATP and NADH (Ref 38
38).
). (Permission granted for reuse of
this figure)
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FIG 1.2 Glucose fermentation in Lactobacillus plantarum. Green arrows point
towards the phosphoketolase
se enzyme within the phosphoketolase pathway of L.
plantarum as a means of producing acetate during glucose fermentation. (1)
phosphoketolase, (2) transaldolase, (3) acetate kinase, (4) transketolase, (5)
phosphoenolpyruvate carboxykinase, (6) malate dehydrogenase, (7) pyruvate
carboxylase, (8) phosphenolpyruvate synthase, (9) pyruvate kinase, (10) pyruvate
formate-lyase,
lyase, (11) phosphotransacetylase, (12) bifunctional alcohol dehydrogenase/
acetaldehyde dehydrogenase, (13) lactate ddehydrogenase (Ref. 41).
). (Permission granted
for the reuse of this figure).
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FIG 1.3 Xfp reaction mechanism. This reaction mechanism proposed by Yevenes et
al. depicts Xfp catalyzed reacti
reaction for the substrate X5P (Ref 16).
). (Permission granted for
reuse of this figure).
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FIG 1.4 Crystal structure of B. breve Xfp homodimer (A) and monomer (B) with
bound TPP.. The monomer is separated into three domains: N
N-terminal
terminal (PP) domain
(blue), Middle (Pyr) domain (yellow) and C
C-terminal
terminal domain (purple). TPP binds to the
active site located between the PP and Pyr domain
domains (Ref. 42).
). (Permission granted for
the reuse of this figure).
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FIG 1.5 Comparison of the estimated number of deaths in Sub
Sub-Saharan
Saharan Africa due
to various infectious diseases (Ref 49).
). (Permission granted for the reuse of this figure).
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FIG 1.6 Infection pathway of Cryptococcus neoformans from the environment to the
host. People come into contact with basidiospores from environmental sources. Spores
are inhaled into the lungs where they can cause immediate pulmonary infection or simply
enter a dormant form. If an individual becomes immunocompromised, the dormant form
can cross the blood brain barrier through hematogenous dissemination and cause
cryptococcal meningitis (Ref. 51
51).
). (Permission granted for the reuse of this figure.)
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FIG. 1.7. Sources of acetate in C. neoformans. Acetate can be produced in C.
neoformans via the Xfp-Ack
Ack pathway, the Pdc
Pdc-Ald pathway or the enzyme Acs.
(Enzyme abbreviations are indicated in the text). The Xfp-Ack
Ack pathway is highlighted at
the top of this figure because it is the pathway focused on throughout this dissertation.
(unpublished data, permission granted for the reuse of this figure by K. Smith).

38

FIG 1.8 Comparison of C. neoformans WT, Acs1 deletion (acs1),
), and Acs1
recomplementation (acs1 + ACS1) strains. Deletion of ACS1 (acs1)) inhibits growth on
sodium acetate, glycerol and ethanol while the ability to grow on these carbon sources is
regained upon ACS1 complementation ((acs1 +ACS1) (A). Deletion of ACS1 (acs1) also
results in attenuated virulence
rulence in a mous
mouse inhalation model (B). (Ref. 70)) (Permission
granted for the reuse of this figure).
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CHAPTER 2
BIOCHEMICAL AND KINETIC CHARACTERIZATION OF XYLULOSE 5PHOSPHATE/ FRUCTOSE 6-PHOSPHATE PHOSPHOKETOLASE 2 (XFP2) FROM
CRYPTOCOCCUS NEOFORMANS

Katie Glenn, Cheryl Ingram-Smith, and Kerry S. Smith

I. ABSTRACT

Xylulose 5-phosphate/fructose 6-phosphate phosphoketolase (Xfp), previously
thought to only be present in bacteria but recently found in fungi, catalyzes the formation
of acetyl phosphate from xylulose 5-phosphate or fructose 6-phosphate. Here we
describe the first biochemical and kinetic characterization of a eukaryotic Xfp, that from
the opportunistic fungal pathogen Cryptococcus neoformans, which has two XFP genes
(designated XFP1 and XFP2). Our kinetic characterization of C. neoformans Xfp2
indicated the existence of both substrate cooperativity for all three substrates and
allosteric regulation through the binding of effector molecules at sites separate from the
active site. Prior to this study Xfp enzymes from two bacterial genera had been
characterized and were determined to follow Michaelis-Menten kinetics. C. neoformans
Xfp2 is inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic acid (OAA) and
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activated by AMP. ATP is the strongest inhibitor with a half maximal inhibitory
concentration (IC50) of 0.6 mM.

PEP and OAA were found to share the same or have

overlapping allosteric binding sites while ATP binds at a separate site. AMP acts as a
very potent activator; as little as 20 µM AMP is capable of increasing Xfp2 activity by
24.8 ± 1.0% while 50 µM prevented inhibition by 0.6 mM ATP. AMP and PEP/OAA
operated independently, with AMP activating Xfp2 and PEP/OAA inhibiting the
activated enzyme. This study provides valuable insight into the metabolic role of Xfp
within fungi, specifically the fungal pathogen Cryptococcus neoformans, and suggests
that at least some Xfps display substrate cooperative binding and allosteric regulation.
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II. INTRODUCTION

Cryptococcus neoformans, an invasive opportunistic pathogen of the central
nervous system, is the most frequent cause of fungal meningitis resulting in more than
625,000 deaths per year worldwide (1,2). Exposure to C. neoformans is common, as it is
an environmental fungus found in the soil and can enter the lungs through inhalation,
leading to pulmonary infection. An increased rate of infection occurs in individuals with
impaired cell-mediated immunity, particularly those with AIDS and recipients of
immunosuppressive therapy.
Acetate has been shown to be a major metabolite released by Cryptococcus during
infection (3-5), but the significance of this is not known. Genes encoding enzymes from
three putative acetate-producing pathways and two putative acetate transporters have
been shown to be upregulated during cryptococcal infection (6), suggesting acetate
production and transport may be a necessary and required part of the pathogenic process.
One pathway for acetate production is composed of the enzymes xylulose 5phosphate/ fructose 6-phosphate phosphoketolase (Xfp) and acetate kinase (Ack). Xfp
catalyzes the breakdown of xylulose 5-phosphate (X5P; X5P + Pi ↔ acetyl-phosphate +
glyceraldehyde 3-phosphate; EC 4.1.2.9) or fructose 6-phosphate (F6P; F6P + Pi ↔
acetyl phosphate + erythrose 4-phosphate; EC 4.1.2.22). Ack utilizes the acetyl
phosphate product of the reaction to produce acetate + ATP (acetate + ATP ↔ acetyl
phosphate +ADP; EC 2.7.2.1). These enzymes form a modified pathway, termed the
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pentose phosphoketolase pathway, in lactic acid bacteria and bifidobacteria (7). This
pathway is utilized in the heterofermentative degradation of pentoses and hexoses to the
end products CO2, ethanol, acetate and lactate (8). Xfp can convert X5P generated at the
end of the oxidative phase of the pentose phosphate pathway to glyceraldehyde 3phosphate, which can enter the glycolytic pathway, and acetyl phosphate, which Ack can
convert to acetate to generate ATP.
Only the Xfp enzymes from the lactic acid bacteria Bifidobacterium species and
Lactobacillus plantarum have been purified and kinetically characterized (7,9). The
characterized bacterial Xfp enzymes show dual substrate specificity with X5P and F6P
and follow Michaelis-Menten kinetics (7,9,10). Here we report the first biochemical and
kinetic characterization of eukaryotic Xfp, the C. neoformans Xfp2 (Accession #
CNAG_06923.7). Unlike the previously characterized bacterial Xfp enzymes, C.
neoformans Xfp2 displays both substrate cooperativity and allosteric regulation. The
enzyme is inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic acid (OAA)
and activated by AMP.
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III. MATERIALS AND METHODS

Materials
Chemicals were purchased from Sigma Aldrich, VWR, or Fisher Scientific.
Oglionucleotide primers were purchased from Integrated DNA Technologies. Codonoptimized C. neoformans XFP2 was synthesized by GenScript and supplied in the E. coli
expression vector pET21b which provides for addition of a C-terminal His-tag for nickel
affinity column purification.
Production and Purification of C. neoformans Xfp2
The recombinant plasmid pET21b-XFP2 was transformed into Escherichia coli
RosettaBlue (DE3) placI (Novagen). The recombinant strain was grown in Luria-Bertani
(LB) medium with 50 µg/mL of ampicillin and 34 µg/mL of chloramphenicol at 37°C to
an absorbance of ~0.8 at 600 nm, and production of the enzyme was induced by the
addition of IPTG to a final concentration of 1 mM. Cultures were incubated overnight at
ambient temperature and cells were harvested by centrifugation and stored at -20°C prior
to protein purification.
Cell-free extract was prepared by first suspending the cells in buffer A (25 mM
Tris, 150 mM sodium chloride, 20 mM imidazole, 1 mM dithiothreitol (DTT) and 10%
glycerol [pH 7.4]), and passing twice through a French pressure cell at approximately 130
MPa. The cell extract was clarified by ultracentrifugation at 100,000 x g for 1 hour, and
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then subjected to column chromatography using an AKTA-FPLC (GE Healthcare). Cellfree extract was applied to a 5 mL His-Trap HP column (GE Healthcare). After a 6 to 7
column volume wash with buffer A to remove any unbound protein, the column was
developed with a linear gradient from 0 to 0.5 M imidazole in buffer A. Appropriate
fractions determined to contain Xfp2 by SDS-PAGE and activity assays were pooled and
dialyzed overnight in buffer containing 25 mM Tris, 10% glycerol and 1 mM DTT [pH
7.0]. Aliquots of purified protein were stored at -80°C. Protein concentration was
determined using a modified Bradford assay with bovine serum albumin standards.
Hydroxamate Assay Measuring Acetyl Phosphate Production
Enzymatic activity was measured using the hydroxamate assay to quantitate the
production of acetyl phosphate (9,11). Standard reactions consisted of 0.5 mM thiamine
pyrophosphate (TPP), 1 mM DTT, 5 mM magnesium chloride, and 50 mM MES buffer
(pH 5.5 for all kinetic studies), with the concentration of substrates varied. The sodium
phosphate substrate was used at a pH of 5.5.
Reactions (200 µL) were initiated by the addition of enzyme and incubated at 40
°C. After 30 minutes, 100 µL of 2 M hydroxylamine hydrochloride (pH 7.0) was added
and the reactions were allowed to incubate at room temperature for 10 minutes.
Reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 % FeCl3
in 2N HCl and 10% trichloroacetic acid to form the ferric-hydroxamate complex which
was measured spectrophotometrically at 540nm (7,12). Reactions were performed in
triplicate for all data sets.
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Kinetic Analysis
Apparent kinetic parameters were determined by varying the concentration of one
substrate with the other substrate held constant at a saturating level (60 mM for Pi or
F6P). All substrates exhibited varying degrees of cooperativity, and kinetic parameters
were determined by fitting the data to the Hill equation [Eq. 2.1] (13,14) in which V0 is
initial velocity, [S] is substrate concentration, V is maximum velocity, K0.5 is substrate
concentration at half maximal velocity and h is the Hill constant. Data was plotted using
the scientific graphing program Kaleidagraph (Synergy Software).
     /

.

  

[Eq. 2.1]

Determination of IC50 Values and Allosteric Binding Site Sharing of Xfp2 Inhibitors
After determining kinetic parameters for X5P commercial availability was
discontinued, so our investigations into the allosteric regulation of Xfp2 were performed
only with F6P. Half maximal inhibitory concentrations (IC50) were determined for all
Xfp2 allosteric inhibitors by measuring the decrease in activity as a function of increasing
inhibitor concentration. GraphPad Prism 5 software was used to determine IC50 values
by fitting the data with a log [inhibitor] vs. response curve. In order to determine if any
of the inhibitors bind at the same allosteric site or have overlapping allosteric sites, the
IC50 value of one inhibitor was measured in the presence of another inhibitor.
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IV. RESULTS

Optimization of reaction conditions
An E. coli codon-optimized XFP2 (GenScript Inc.) was cloned into pET21b (Cterminal His tag) and the recombinant enzyme was produced and purified by nickel
affinity chromatography to electrophoretic homogeneity. Optimal reaction conditions for
purified Xfp2 activity were determined. The temperature optimum was found to be 3740°C (Fig. 2.1A), the temperature that C. neoformans would be exposed to during
infection. Xfp2 had highest activity between pH 4.5 and 6.0 (Fig. 2.1B), and pH 5.5 was
used when determining kinetic parameters. Like its bacterial counterpart, C. neoformans
Xfp2 requires the cofactor thiamine pyrophosphate (TPP), and 0.5 mM TPP was
sufficient for full enzymatic activity (data not shown). Xfp2 prefers Mg2+ as the divalent
cation, but can also utilize Ca2+, Co2+, Mn2+, and Ni2+ (Fig. 2.1C).
Kinetic characterization of C. neoformans Xfp
In determining the kinetic parameters in the acetyl phosphate-forming direction,
plots of substrate concentration versus velocity were found to be sigmoidal rather than
hyperbolic as would be expected for enzymes following Michaelis-Menten kinetics. This
is the first demonstration of the existence of substrate cooperative binding among Xfp
enzymes which was not reported in previous characterizations of bacterial Xfps (7,9,10).
Apparent kinetic parameters (Table 2.1) were determined by fitting experimental data to
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the Hill equation [Eq 2.1] in which a Hill constant greater than 1.0 represents positive
cooperativity and a Hill constant less than 1.0 represents negative cooperativity (15,16)
Xfp2 exhibits positive cooperativity (h >1.0) for both X5P and F6P, suggesting that
binding of either of these substrates causes a favorable conformational change that
facilities the binding of additional substrate at separate active sites on the enzyme. Xfp2
displays negative cooperativity (h < 1.0) for Pi with an average Hill constant of
approximately 0.6. The 2.6-fold higher catalytic efficiency suggests that X5P is slightly
preferred over F6P.
Allosteric Inhibitors
Since we hypothesize that the Xfp-Ack pathway plays a significant role in ATP
production during infection, it would seem likely that this pathway would be regulated,
particularly since the F6P substrate of Xfp2 is an intermediate in glycolysis, another key
ATP-generating pathway that has been shown to be critical for virulence (17). ATP along
with coenzymes and intermediates from glycolysis and the tricarboxylic acid (TCA)
cycle were tested to see if Xfp2 is allosterically regulated by these molecules. Of the
ligands tested, ATP, phosphoenolpyruvate (PEP), and oxaloacetic acid (OAA) were
found to display the most pronounced inhibition (Fig. 2.2) while citrate caused slight
inhibition (data not shown). Acetyl-CoA, CoA, and pyruvic acid were also tested and
had no effect on activity. Progress curves for both substrates Pi and F6P were generated
in the presence of increasing concentrations of ATP (Fig. 2.3A & B), PEP (Fig. 2.4A &
B), and OAA (Fig. 2.5A & B).
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For each of the three inhibitors, the K0.5 for Pi was not significantly affected (data
not shown); however, the K0.5 concentrations for F6P increased in each case. The K0.5 for
F6P increased from 15.9 ± 1.3 mM in the absence of inhibitor to 73.9 ± 3.2 mM in the
presence of 9 mM ATP, 109.4 ± 6.9 mM in the presence of 15 mM OAA, and 69.3 ± 9.6
mM in the presence of 16 mM PEP. The addition of inhibitor also generated a more
sigmoidal F6P progress curve that is reflected by the increase in the Hill coefficient. The
Hill coefficient increased from 1.41 ± 0.11 to 4.50 ± 0.20, 2.32 ± 0.07, and 2.40 ± 0.30 in
the presence of 9 mM ATP, 15 mM OAA and 16 mM PEP respectively. This suggests
that the binding of ATP, PEP and OAA has a direct effect on the binding of F6P to the
active site in order to more closely regulate Xfp2 activity in response to changing cellular
concentrations of these effectors.
The IC50 concentrations, the concentration of inhibitor required to reduce activity
to half its maximally inhibited value, were determined for each inhibitor using the K0.5
concentrations of both Pi (13 mM) and F6P (16 mM) (Table 2). The IC50 value of 0.6
mM for ATP is much lower than those determined for PEP and OAA, which were very
similar (Table 2.2). Since both molecules are similar in size and structure, it is possible
that they bind at the same allosteric site. In order to test if the inhibitors share the same
allosteric site, reactions were performed in which one inhibitor was held constant at its
IC50 concentration and the concentration of the second inhibitor was varied. If two
inhibitors bind at the same site (or if binding of one inhibitor occludes the binding of the
second) then approximately half of the binding sites would be occupied by the first
inhibitor, thereby lowering the concentration of the second (varied) inhibitor required to
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inhibit activity by an additional 50%. The IC50 of PEP decreased by approximately half
in the presence of OAA; likewise the IC50 value of OAA decreased by about half in the
presence of PEP (Table 2.2). This suggests that PEP and OAA share the same allosteric
site. Alternatively, PEP and OAA bind at separate overlapping sites in which the binding
of one inhibitor prevents the binding of the second inhibitor. The IC50 of PEP in the
presence of ATP did not change significantly suggesting that the PEP/OAA site(s) is
separate from the ATP allosteric site.
Allosteric Activator
C. neoformans Xfp2 is activated by the presence of AMP (Fig 2.6). The presence
of as little as 20 µM AMP resulted in elevated enzymatic activity that reached a
maximum at 0.5 mM AMP. The half maximal activation concentration was determined
to be 29.7 ± 1.5 µM. The effect of AMP activation on Pi and F6P progress curves was
evaluated. Increasing amounts of AMP resulted in increased Xfp2 activity at all Pi
concentrations without affecting the overall shape of the curve or the K0.5 of Pi (Fig.
2.6A). Therefore, AMP does not appear to have a direct effect on the binding of Pi to the
active site. The presence of AMP decreased the K0.5 for F6P from 15.9 ± 1.3 mM in the
absence of AMP to 9.1 ± 0.6 mM in the presence of 0.5 mM AMP. Increasing
concentrations of AMP resulted in more hyperbolic F6P progress curves (Fig. 2.6B). The
Hill coefficient decreased from 1.41 ± 0.11 in the absence of AMP to 0.97 ± 0.03 in the
presence of 0.5 mM AMP, suggesting more constant affinity for the substrate F6P.
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AMP not only causes activation but alleviates the effects of allosteric inhibitors
(Fig. 2.7). The presence of AMP completely prevents or overrides the inhibitory effect of
ATP. However, AMP cannot overcome inhibition by PEP. The results observed are
consistent with AMP and PEP acting separately, with AMP fully activating the enzyme,
and PEP inhibiting from this fully activated level. When ATP and PEP are both present,
inhibition is slightly additive compared to the inhibition by either one alone. Activity
decreased from 43.4 ± 0.7% in the presence of PEP to 32.5 ± 0.6% when both ATP and
PEP are present. The level of activity observed when AMP was present in addition to
PEP was similar to that when AMP was present with both ATP + PEP. In both cases,
activity was in the range expected for inhibition of the fully activated enzyme by the IC50
concentration of PEP.
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V. DISCUSSION

Here we report the first characterization of C. neoformans Xfp2, the first
eukaryotic Xfp to be characterized. Xfp functions with Ack in heterofermentative
bacteria to form a modified pentose phosphoketolase pathway. This pathway was
originally thought to be present only in bacteria but has been more recently identified in
euascomycete and basidiomycete fungi (18). Like C. neoformans, many fungi with this
pathway have two XFP ORFs designated as XFP1 and XFP2.
Unlike previously characterized bacterial Xfps, C. neoformans Xfp2 displays both
substrate cooperative binding and allosteric regulation. Xfp2 is allosterically regulated
by the activator AMP and inhibitors ATP, PEP and OAA. PEP and OAA appear to share
the same allosteric binding site while ATP and AMP bind at a separate site. The simplest
explanation of AMP’s ability to fully overcome ATP inhibition is that they bind at the
same site however our results do not conclusively rule out separate but interacting
binding sites. Xfp2 activation by AMP and inhibition by ATP is consistent with Xfp2
partnering with Ack as part of a modified pentose phosphate pathway to generate ATP
and acetate from X5P and F6P. The intracellular ATP:AMP ratio provides an indication
of the cellular energy status and regulation of the Xfp2-Ack pathway by ATP and AMP is
a way to modulate ATP production by this pathway. High ATP levels indicate the energy
needs of the cell have been satisfied and thus additional ATP production via the Xfp2Ack pathway is not necessary, whereas high AMP levels indicate an energy deficit and
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the need for increased ATP production via the Xfp2-Ack pathway. A possible
explanation for Xfp2 inhibition by PEP and OAA is that high concentrations of these
intermediates from glycolysis and the TCA cycle respectively, are also signals that
cellular energy needs have been met, and the cell can switch from glycolysis, which
produces ATP and utilizes glucose, to gluconeogenesis to synthesize and store glucose.
A ping pong bi bi mechanism was originally proposed for Lactobacillus
plantarum Xfp by Yevenes and Frey (9) in which enzyme bound TPP first interacts with
F6P to form a TPP-F6P complex and release the product erythrose 4-phosphate (E4P)
forming enzyme bound 2-α,β-dihydroxyethylidene-TPP (DHETPP). DHETPP undergoes
a dehydration reaction to form enzyme bound enolacetyl-TPP where ketonization
converts it to enzyme bound acetyl-TPP (AcTPP). AcTPP is phosphorylated and acetyl
phosphate is released leaving TPP available to interact with additional F6P substrate and
repeat the reaction. Therefore, the product E4P is formed by the interaction of TPP and
F6P in the absence of the second substrate Pi. The crystal structure of Bifidobacterium
longum Xfp confirmed the reaction mechanism proposed by Yevenes and Frey (19). We
suspect that C. neoformans Xfp2 follows the same active site reaction mechanism as the
bacterial Xfps but with the added complexity of allosteric regulation that influences
substrate-binding affinity. Since all allosteric effectors were found to directly affect F6P
binding, the binding of these effectors influences the interaction between F6P and TPP in
the first step of the reaction mechanism. We found that the presence of allosteric
effectors do not influence the binding of Pi which further confirms and supports the
existence of a ping pong bi bi mechanism in which the interaction between TPP and F6P
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to form E4P occurs in the absence of Pi and that it is this first step of the reaction that is
allosterically regulated.
Acetate is the most abundant metabolite produced during cryptococcal pulmonary
infection, but the role acetate plays in metabolism and infection is unknown (3-5).
Genomic expression studies provide evidence that the Xfp-Ack pathway could be
responsible for acetate production. Serial analysis of gene expression on C. neoformans
cells collected from the lungs of infected mice showed elevated expression of XFP2 (6).
XFP2 was also found to be among the genes upregulated under hypoxic conditions that
occur in infected tissue (20). RNA microarray analysis of C. neoformans gene
expression within the macrophage also indicates that Ack is expressed under this
condition but Xfp2 was not present in this microarray data set (21). In addition an Xfp2
homolog is required for full virulence in the insect fungal pathogen Metarhizium
anisopliae (22). Taken together these studies suggest that C. neoformans Xfp2 may play
a role during infection.
C. neoformans Xfp2 shows maximal activity between 37 - 40°C which is
consistent with a role of Xfp2 during C. neoformans infection (23). The Xfp-Ack
pathway could serve as a source of ATP production under the hypoxic and acidic
conditions encountered in the macrophage where ATP generation by oxidative
phosphorylation is suppressed. In addition, the pH of cryptococcomas has been found to
be between 5.4 and 5.6 in vivo (4). It is possible that the production and excretion of
acetic acid generated by the Xfp-Ack pathway contributes to the acidic environment of
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cryptococcomas. This acidic environment can aid in C. neoformans survival outside the
macrophage by inducing neutrophil necrosis and decreasing superoxide production (4).
Our studies show that Xfp2 functions best at low pH with activity decreasing as pH
increases. Even in vitro assays of the bacterial Xfps were performed below neutral pH,
between pH 6.0 (9) and 6.5(7), and optimal pH was not reported. The intracellular pH of
C. neoformans during infection is unknown, but even though C. neoformans cells are
tolerant to low pH (24), it is unlikely that Xfp2 is exposed to low pH in vivo. The
presence of AMP can increase Xfp2 activity from 13.4 ± 0.7 % to 117.0 ± 2.0 % in the
presence of 0.5 mM AMP at pH 7 with 100% activity considered to be the activity at pH
5.5 using K0.5 substrate concentrations (K. Glenn and K. Smith, unpublished data), so
pH could provide an additional means of regulating Xfp2 activity.
The allosteric regulation that has evolved for C. neoformans Xfp2 versus its
bacterial homolog seems to support a more complex role for this enzyme within fungal
metabolism and during infection. However, allosteric regulation by PEP and OAA but
not AMP and ATP may be occurring with at least some bacterial Xfps (K. Glenn and K.
Smith unpublished data). We believe that Xfp2 partners with Ack to generate ATP,
which is supported by the findings that Xfp2 is regulated by both ATP and AMP levels.
The biochemical properties of this enzyme suggest that it utilizes its partnership with Ack
to generate ATP during infection and within the human macrophage where hypoxic
conditions are encountered that limit ATP production by the electron transport chain.
Xfp2’s involvement in C. neoformans metabolism especially during infection lends
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support to future studies that focus on this enzyme as a possible drug target in the
treatment of cryptococcal infection.
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TABLE 2.1. Apparent kinetic parameters for C. neoformans Xfp2

Substrate
F6P
X5P
Pi

K0.5 (mM)
15.9 ± 1.3
6.4 ± 0.2
13.3 ± 1.5

kcatapp (sec-1)

kcatapp/K0.5 (sec-1mM-1)

H

3.47 ± 0.10
3.76 ± 0.05
4.22 ± 0.13

0.22 ± 0.01
0.58 ± 0.01
0.32 ± 0.03

1.41 ± 0.11
1.17 ± 0.06
0.59 ± 0.03
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TABLE 2.2. Half maximal inhibitory (IC50) concentrations
Inhibitor (Varied)
ATP
PEP
OAA

Inhibitor (Constant)
--------------OAA
ATP
-------PEP
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IC50
0.61 ± 0.04
8.23 ± 0.09
4.84 ± 0.07
9.85 ± 0.25
7.50 ± 0.40
3.71 ± 0.07

A

B

C

FIG 2.1. Optimization of Xfp2 reaction conditions. Xfp2 activity was determined in
the presence of saturating Pi (60 mM) and F6P (80 mM) substrate concentrations for each
reaction condition tested. Activities are reported as percentage of the maximal activity
determined during each assay. (a) Temperature optima for Xfp2. Enzyme reactions were
performed at the indicated temperatures in triplicate. (b) pH optima for Xfp2. Enzyme
reactions were performed utilizing 50mM MES (●) and 50 mM MOPS (○) over a range
of pH values. (c) Divalent cation metal specificity for Xfp2. Enzyme reactions were
performed in the presence of 5 mM metal (as chloride salt).
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FIG 2.2. Effect of various ligands on Xfp2 activity. Various coenzymes and metabolic
intermediates were tested for their effect on Xfp2 activity. Activities are reported as
percentage of maximum activity with no effector present.
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A

B

FIG 2.3. Effect of ATP on substrate progress curves. Progress curves were generated
in the presence of 0 mM (●), 3 mM (○), 6 mM (■) and 9 mM (□) ATP for the substrates
Pi (a) and F6P (b). Activities are reported in micromoles acetyl phosphate produced, and
enzyme reactions were performed in triplicate for each substrate concentration.
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A

B

FIG 2.4. Effect of PEP on substrate progress curves. Progress curves were generated
in the presence of 0 mM (●), 8 mM (○), and 16 mM (■) PEP for the substrates Pi (a) and
F6P (b). Activities are reported in micromoles acetyl phosphate produced, and enzyme
reactions were performed in triplicate for each substrate concentration.
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A

B

FIG 2.5. Effect of OAA on substrate progress curves. Progress curves were generated
in the presence of 0 mM (●), 7.5 mM (○), and 15 mM (■) OAA for the substrates Pi (a)
and F6P (b) Activities are reported in micromoles acetyl phosphate produced, and
enzyme reactions were performed in triplicate for each substrate concentration.

67

A

B

FIG 2.6. Effect of AMP on substrate progress curves. Progress curves were
generated in the presence of 0 mM (●), 0.02 mM (○), 0.1 mM (■), and 0.5 mM (□) AMP
for the substrates Pi (a) and F6P (b). Activities are reported in micromoles acetyl
phosphate produced, and enzyme reactions were performed in triplicate for each substrate
concentration.
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FIG 2.7. AMP activates Xfp2 activity and alleviates inhibition by allosteric
inhibitors. Activities are reported as percentage of the maximum activity with no
allosteric effector present. The effectors AMP, ATP and/ or PEP were added to reactions
alone or in combination at final concentrations of 0.5 mM, 0.6 mM and 8 mM
respectively.
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CHAPTER 3
ALLOSTERIC REGULATION OF LACTOBACILLUS PLANTARUM XYLULOSE 5PHOSPHATE/ FRUCTOSE 6-PHOSPHATE PHOSPHOKETOLASE (XFP)

Katie Glenn and Kerry S. Smith

I. ABSTRACT

Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp), which
catalyzes the conversion of xylulose 5-phosphate (X5P) or fructose 6-phosphate (F6P) to
acetyl phosphate, plays a key role in carbohydrate metabolism in a number of bacteria.
Recently we demonstrated that the fungal Cryptococcus neoformans Xfp2 exhibits both
substrate cooperativity for all substrates (X5P, F6P and Pi) and allosteric regulation in the
form of inhibition by phosphoenolpyruvate (PEP), oxaloacetic acid (OAA) and ATP and
activation by AMP. Allosteric regulation has not previously been reported for the
characterized bacterial Xfps. Here we report the discovery of substrate cooperativity and
allosteric regulation among bacterial Xfps, specifically the Lactobacillus plantarum Xfp.
L. plantarum Xfp was found to be an allosteric enzyme inhibited by PEP, OAA and
glyoxylate but unaffected by the presence of ATP or AMP. Glyoxylate was also found to
be an additional inhibitor to those previously reported for C. neoformans Xfp2. As with
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C. neoformans Xfp2, PEP and OAA share the same or possess overlapping sites on L.
plantarum Xfp. Glyoxylate, which had the lowest half maximal inhibitory concentration
of the three inhibitors, binds at a separate site. This study demonstrates that substrate
cooperativity and allosteric regulation may be common properties among bacterial and
eukaryotic Xfp enzymes, yet important differences exist between the enzymes in these
two domains.
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II. INTRODUCTION

Xylulose 5-phosphate (X5P)/ fructose 6-phosphate (F6P) phosphoketolase (Xfp),
a member of the thiamine pyrophosphate (TPP) dependent enzyme family, catalyzes the
production of acetyl phosphate from the breakdown of xylulose 5-phosphate (equation
1a; EC 4.1.2.9) or fructose 6-phosphate (equation 1b; EC 4.1.2.22). In lactic acid
bacteria and bifidobacteria, Xfp partners with either acetate kinase (Ack) to generate
acetate and ATP (equation 2) or phosphotransacetylase (Pta) to generate acetyl-CoA and
Pi (equation 3) (1,2). Xfp open reading frames (ORFs) have more recently been
discovered in euscomycete and basidiomycete fungi as well (3). In fungi, Xfp is believed
to partner with Ack since all fungi that have an Ack ORF have at least one, and in some
cases two, Xfp ORFs but lack Pta (3).
X5P + Pi ↔ Glyceraldehyde 3-phosphate + Acetyl phosphate
F6P + Pi ↔ Erythrose 4-phosphate + Acetyl phosphate

(1a)
(1b)

Acetyl phosphate + ADP ↔ Acetate + ATP

(2)

Acetyl-CoA + Pi ↔ Acetyl phosphate + CoA

(3)

Xfp has been biochemically and kinetically characterized from several bacterial
species, including Lactobacillus plantarum (referred to by Yevenes et al. as L. plantarum
Xpk2) (2), Bifidobacterium spp. (1,4), Lactococcus lactis(5), Leuconostoc mesenteroides
(5), and Pseudomonas aeruginosa (5), and more recently one fungal species,
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Cryptococcus neoformans Xfp2 (6). The Bifidobacterium Xfp L. plantarum, L. lactis, L.
mesenteroides, and P. aeruginosa Xfps displayed dual substrate specificity for both
substrates X5P and F6P and followed Michaelis-Menten kinetics (1,2,4,5). C.
neoformans Xfp2 also displays dual substrate specificity but does not follow MichaelisMenten kinetics (6). Instead, kinetic characterization of C. neoformans Xfp2 indicated
the existence of both substrate cooperativity and allosteric regulation. C. neoformans
Xfp2 was found to be inhibited by ATP, phosphoenolpyruvate (PEP) and oxaloacetic
acid (OAA) and activated by AMP (6). Substrate cooperativity and allosteric regulation
have not been reported for any characterized bacterial Xfp (1,2,4,5).
In this paper we describe the characterization of L. plantarum Xfp in which
kinetic parameters were determined using the Hill equation and the influence of potential
allosteric effectors on L. plantarum Xfp activity was examined. L. plantarum Xfp was
found to be an allosteric enzyme inhibited by PEP and OAA but unaffected by the
presence of AMP or ATP. Additionally, glyoxylate was discovered to be an inhibitor of
both C. neoformans Xfp2 and L. plantarum Xfp.
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III. MATERIALS AND METHODS

Materials
All chemicals were purchased from Sigma Aldrich, VWR, Fisher Scientific, or
Gold Biotechnology. The recombinant plasmid pET28b-xpk2 in Escherichia coli BL21
(DE3) was kindly provided by Dr. Perry Frey (University of Wisconsin-Madison) for
production of recombinant L. plantarum Xfp (2).
Production and Purification of Recombinant L. plantarum Xfp
BL21 (DE3) containing the recombinant plasmid pET28b-xpk2 was grown in
Luria-Bertani (LB) medium with 25 µg/mL kanamycin at 37 °C to an absorbance of ~0.8
at 600 nm. Recombinant L. plantarum Xfp production was induced by the addition of 1
mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were allowed to grow
overnight at room temperature and harvested by centrifugation.
Cells were suspended in buffer A (25 mM Tris, 150 mM sodium chloride, 20 mM
imidazole, 1 mM dithiothreitol (DTT) and 10% glycerol [pH 7.4]) and lysed by two
passages through a French pressure cell at approximately 130MPa. Cell lysate was
clarified by ultracentrifugation at 100,000 x g for 1.5 hours. The supernatant was applied
to a 5 mL His-Trap HP column (GE Healthcare) and subjected to column
chromatography using an AKTA-FPLC (GE Healthcare). After washing with at least
seven column volumes of buffer A to remove any unbound protein, the column was
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subjected to a linear gradient of 20 to 500 mM imidazole to remove all column-bound
protein. Fractions determined to contain L. plantarum Xfp by SDS-PAGE and activity
assays were pooled and dialyzed overnight against buffer containing 25 mM Tris, 1 mM
DTT, and 10% glycerol [pH 7.0]. Protein concentration was determined using a modified
Bradford assay (7) with bovine serum albumin as standard, and purified protein was
stored at -80°C.
Production and Purification of Recombinant C. neoformans Xfp2
The recombinant plasmid pET21b-XFP2 synthesized by GenScript was
transformed into the E. coli expression strain RosettaBlue™ (Novagen). The
recombinant strain was grown in LB medium supplemented with 1 % dextrose, to reduce
basal level transcription from the T7 RNA polymerase gene under the control of L8-UV5
promoter in the DE3 prophage prior to the addition of IPTG, and 50 µg/mL ampicillin
and 34 µg/mL chloramphenicol. At an absorbance of ~0.8 at 600 nm, IPTG was added to
a final concentration of 1 mM to induce production of the enzyme. Expression was
allowed to proceed overnight at room temperature, and cells were harvested by
centrifugation. Recombinant C. neoformans Xfp2 was purified as previously described
(6).
Xfp Assay
Enzymatic activity was measured using the hydroxamate assay to detect the production of
acetyl phosphate (1,2,6,8). A standard 200 µL reaction contained 0.5 mM thiamine
pyrophosphate (TPP), 1 mM DTT, 5 mM magnesium chloride, and 50 mM MES (at pH
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6.0 for L. plantarum Xfp assays and pH 5.5 for C. neoformans Xfp2 assays) with varied
concentrations of the substrates F6P and Pi, in the form of sodium phosphate pH 6.0 for
L. plantarum Xfp and pH 5.5 for C. neoformans Xfp2. Reactions were initiated by the
addition of enzyme and allowed to proceed for 30 minutes at 37°C for L. plantarum Xfp
and 40°C for C. neoformans Xfp2. After 30 minutes, 100 µL of 2 M hydroxylamine
hydrochloride (pH 7.0) was added, and reactions were allowed to incubate at room
temperature for 10 minutes to fully convert all acetyl phosphate to acetyl hydroxamate.
Reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 % ferric
chloride in 2N hydrochloric acid and 10 % trichloroacetic acid to generate the ferrichydroxamate complex. The color change due to product formation was measured by a
change in absorbance at 540 nm. All data sets correspond to reactions performed in
triplicate.
L. plantarum Xfp Kinetic Analysis
To determine L. plantarum Xfp kinetic parameters, one substrate was varied
while the other substrate was held constant at a saturating concentration (60 mM for F6P
and 8 mM for Pi). Since the commercial availability of X5P has been discontinued, all
kinetic parameters were determined using F6P. Data was plotted using KaleidaGraph
software (Synergy), and kinetic parameters were found by applying the Hill equation
(equation 4) (9,10) to the data set where V0 is initial velocity, [S] is substrate
concentration, V is maximum velocity, K0.5 is substrate concentration at half maximal
velocity and h is the Hill constant.
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Determination of Inhibitor IC50 Values (Individually and in Combination)
The half maximal inhibitory concentration (IC50) was determined for each L.
plantarum Xfp inhibitor and an additional C. neoformans Xfp2 inhibitor not previously
described by measuring the decrease in enzyme activity at K0.5 substrate concentrations
(11 mM F6P and 1 mM Pi for L. plantarum Xfp and 16 mM F6P and 13 mM Pi for C.
neoformans Xfp2) in the presence of increasing inhibitor concentration. The IC50 was
found by fitting the data with a log [inhibitor] vs response curve in Graphpad Prism 5
software. In order to determine if inhibitors share the same or overlapping allosteric
binding sites the effect on IC50 of one inhibitor in the presence of another inhibitor was
measured.
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IV. RESULTS

Effect of pH on L. plantarum Xfp Activity
Recombinant L. plantarum Xfp was produced and purified using nickel affinity
chromatography. It was previously discovered that C. neoformans Xfp2 activity is
significantly reduced with increasing pH and that maximal activity occurs between pH
4.5 and 6.0 (6). Like C. neoformans Xfp2, L. plantarum Xfp activity decreases with
increasing pH. However, the decrease in activity does not occur until pH 6.5 versus pH
6.0 for C. neoformans Xfp2 (Fig. 1) suggesting that L. plantarum Xfp is slightly more
tolerant to elevated pH than C. neoformans Xfp2. Maximum L. plantarum Xfp activity
occurs around pH 6.0 which was used in all kinetic assays.
Kinetic Characterization of L. plantarum Xfp
We have recently shown that C. neoformans Xfp2 displays substrate cooperativity
and is subject to allosteric regulation (6), neither of which have been reported for any of
the bacterial Xfp enzymes (1,4,5,11), including the L. plantarum Xfp (2). To establish
whether substrate cooperativity exists for L. plantarum Xfp, apparent kinetic parameters
(Table 1) were determined in the acetyl phosphate forming direction for the substrates
F6P and Pi by fitting the Hill equation to plots of substrate concentration versus velocity.
L. plantarum Xfp displays negative cooperativity for Pi as indicated by a Hill constant of
0.68 ± 0.02, similar to the Hill constant of 0.59 ± 0.03 for the C. neoformans enzyme (6).
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The K0.5 value of 1.0 ± 0.1 mM for Pi is similar to the Km previously determined for the L.
plantarum enzyme (2).
Unlike C. neoformans Xfp2, L. plantarum Xfp Hill constant of approximately 1.0
does not indicate the existence of substrate cooperativity in regards to F6P binding. F6P
progress curves for L. plantarum Xfp were found to fit both the Michaelis-Menten and
Hill equations equally well with R values around 0.99. Using the Michaelis-Menten
equation Kmapp for F6P was determined to be 10.8 ± 0.8 mM, while a K0.5 for F6P of 11.0
± 1.4 mM was calculated using the Hill equation for the same data set. Both F6P K0.5 and
Kmapp are on the same order of magnitude as the Kmapp for F6P previously determined by
Yevenes et al. (2).
L. plantarum Xfp is Inhibited by PEP and OAA, but Unaffected by AMP and ATP.
The same ligands examined as possible allosteric effectors of C. neoformans Xfp2
(6) were tested to determine their effect on L. plantarum Xfp activity. As with C.
neoformans Xfp2, L. plantarum Xfp is inhibited by phosphoenolpyruvate (PEP) and
oxaloacetic acid (OAA) (Fig. 2) and slightly inhibited by citrate (data not shown). L.
plantarum Xfp activity was unaffected by the presence of AMP or ATP, the primary
allosteric activator and inhibitor, respectively, of C. neoformans Xfp2. Additional
ligands tested such as acetate and pyruvic acid that had no effect on C. neoformans Xfp2
activity also had no effect on L. plantarum Xfp activity.
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Glyoxylate Inhibits both L. plantarum Xfp and C. neoformans Xfp2 Activity
Since PEP and OAA serve as common allosteric effectors for bacterial L.
plantarum Xfp and eukaryotic C. neoformans Xfp2, various PEP analogs were tested to
determine the specificity of this allosteric site for PEP and the primary chemical moiety
that contributes to the allosteric inhibitory effect. Non-phosphorylated PEP analogs have
previously been utilized to determine the chemical moiety that contributes to allostery in
muscle pyruvate kinase (12), and each of these PEP analogs were used to test L.
plantarum Xfp inhibition (Fig. 3a). Interestingly, glyoxylate was found to inhibit Xfp in
addition to PEP and OAA. L. plantarum Xfp was almost fully inhibited by 8 mM
glyoxylate with only 7.2 ± 1.0% activity remaining but only partially inhibited by 8 mM
PEP (45.7 ± 3.4% activity remaining). Pyruvate showed no inhibition while the PEP
analogs D-lactate, L-lactate, methyl pyruvate, hydroxyacetone, and glycolate displayed
intermediate levels of inhibition. These same PEP analogs were used to test their
inhibitory effect against C. neoformans Xfp2 as well, and the results were similar to those
found for the L. plantarum Xfp. Glyoxylate also inhibits C. neoformans Xfp2 activity,
with 8 mM reducing activity to 15.3 ± 1.0%. Similar to L. plantarum Xfp, pyruvate had
no effect on C. neoformans Xfp2 activity while all other PEP analogs show intermediate
inhibition between that of pyruvate and glyoxylate (Fig. 3b).
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Determination of Allosteric Effector Half Maximal Inhibitory Concentrations
(IC50s)
The IC50 half maximal inhibitory concentration was determined for each L.
plantarum Xfp inhibitor (Table 2) using K0.5 substrate concentrations. The IC50 for
glyoxylate was lower than those for PEP and OAA by approximately 3-fold and 5-fold,
respectively. In order to determine if any of these inhibitors share the same site, the IC50
of one inhibitor was determined in the presence of a second inhibitor held constant at its
IC50. If two inhibitors share the same site or if their sites overlap, then approximately
half the sites should be occupied by the inhibitor held constant thereby lowering the
amount of the varied inhibitor required to reduce activity by an additional 50%.
In the presence of 10.5 mM OAA, the PEP IC50 decreased more than half the
original value, demonstrating that the L. plantarum PEP and OAA binding sites are the
same or overlapping, as indicted previously for C. neoformans Xfp2 (6). The reason the
IC50 of PEP is reduced by more than half in the presence of OAA is most likely due to the
unique inhibitory effect of OAA (Fig 4a) not seen in glyoxylate (Fig 4b) or PEP (Fig 4c)
inhibition profiles. High concentrations of OAA were required to initiate L. plantarum
Xfp inhibition followed by a sharp decrease in activity in the presence of additional OAA
(Fig 4a). This inhibitory concentration threshold may suggest that PEP and OAA interact
with the binding site differently or that these are overlapping instead of identical binding
sites. The IC50 of PEP does not change significantly in the presence of 2 mM glyoxylate
while the IC50 of OAA decreases by approximately 26%. Therefore, it appears that the
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PEP/OAA site is separate from the glyoxylate site since neither PEP nor OAA IC50
display close to a 50% decrease in the presence of 2 mM glyoxylate.
Since glyoxylate was not previously recognized as an Xfp inhibitor (6), the IC50
of glyoxylate was determined for C. neoformans Xfp2 (Table 2). The C. neoformans
Xfp2 PEP IC50 of 5.31 ± 0.13 mM, slightly lower than the 8 mM IC50 previously
reported, (6) decreased to 4.01 ± 0.07 mM in the presence of 5 mM glyoxylate. Since the
IC50 of PEP only decreases by about 24% in the presence of 5 mM glyoxylate, it is likely
that the binding of PEP and glyoxylate occur at separate sites on C. neoformans Xfp2 as
well.
Allosteric Inhibitors Influence F6P Binding
Progress curves of substrate concentration versus activity were generated for L.
plantarum Xfp substrates F6P and Pi in the presence of increasing PEP concentrations
(Fig. 5). The presence of PEP had the same effect on L. plantarum Xfp kinetic
parameters as it did for C. neoformans Xfp2 (6). In regards to Pi, the presence of PEP
had little effect on K0.5, which remained between 1.0 ± 0.03 mM and 1.3 ± 0.30 mM at 0
mM PEP and 16 mM PEP respectively, or Hill constant, which ranged between 0.66 ±
0.01 and 0.49 ± 0.02. However, a gradual reduction in Vmax from 1.06 ± 0.01 µmol of
product formed per 30 minute reaction at 0 mM PEP to 0.80 ± 0.04 µmol at 16 mM PEP
was observed. The K0.5 of F6P increased from 9.8 ± 0.2 mM in the absence of inhibitor
to 37.8 ± 0.9 mM in the presence of 16 mM F6P and the Hill constant also increased from
1.31 ± 0.01 to 1.79 ± 0.01. The presence of PEP had little effect on F6P maximal activity
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with Vmax ranging between 0.93 ± 0.02 and 0.87 ± 0.01 µmol of product formed per 30
minute reaction. Since PEP and OAA bind at the same or overlapping sites on L.
plantarum Xfp, PEP was utilized to represent the effect of both PEP and OAA inhibition
on substrate binding. The influence that PEP inhibition has on the F6P K0.5 and Hill
constant suggests that, similar to C. neoformans Xfp2 (6), the binding of PEP and OAA
directly influences the binding of F6P to the L. plantarum Xfp active site. Glyoxylate
binding did not significantly influence F6P K0.5 but had a greater influence on Vmax (data
not shown).
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V. DISCUSSION

Recently we determined that a fungal Xfp, C. neoformans Xfp2, displayed both
substrate cooperativity (positive cooperativity for F6P and negative cooperativity for Pi)
and allosteric regulation in the form of inhibition through the binding of ATP, PEP and
OAA and activation by the binding of AMP (6). Here we report the discovery of
substrate cooperativity and allosteric regulation for bacterial L. plantarum Xfp. This
report describes the first indication that substrate cooperativity and allosteric regulation
also exists among at least some bacterial Xfp enzymes. Kinetic parameters for L.
plantarum Xfp were originally determined by Yevenes et al. by fitting substrate progress
curves with the Michaelis-Menten equation to determine apparent binding constants Km
for F6P and Pi which were found to be 24 ± 4 mM and 2.9 ± 0.5 mM respectively (2).
We produced the recombinant L. plantarum Xfp and demonstrated that this enzyme
displays negative cooperativity in regards to Pi binding with a Hill constant less than one
but little cooperativity in regards to F6P binding with a Hill constant roughly equal to
one.
In addition to substrate cooperativity, L. plantarum Xfp, like C. neoformans Xfp2,
is allosterically regulated. It is inhibited by PEP and OAA, but unlike C. neoforamans
Xfp2 the presence of ATP or AMP had little to no effect on activity. Initially L.
plantarum Xfp kinetic parameters did not suggest the presence of substrate cooperativity
for F6P binding alone however the presence of the inhibitor PEP induces positive

84

cooperativity as demonstrated by the sigmoidal progress curves and increase in F6P Hill
constant shown in Fig. 5. Unlike PEP, glyoxylate inhibits enzyme activity without
greatly influencing F6P binding since both F6P Km and Hill constant were not greatly
altered. In regards to C. neoformans Xfp2 and L. plantarum Xfp regulation by excess
PEP and OAA, the presence of these intermediates indicate the energy needs of the cell
have been met. The cell can switch from glycolysis, the breakdown of glucose, to
gluconeogenesis to synthesize and ultimately store glucose until it is needed, and
therefore, Xfp may be inhibited by these intermediates in order to limit additional energy
production through the Xfp/Ack pathway (6).
In addition to Xfp, L. plantarum can produce acetyl phosphate from pyruvate
using pyruvate oxidase (Pox) and from acetyl-CoA using phosphotransacetylase (Pta). It
has been shown that at least some Acks in heterofermentative bacteria are allosterically
regulated (13). Perhaps Xfp regulation by the presence of ATP and AMP is less
necessary in L. plantarum that has additional sources for acetyl phosphate production and
may also possess an allosterically regulated Ack, though this has not been experimentally
proven. Xfp regulation by ATP and AMP may have evolved in C. neoformans where
there is no evidence of an allosterically regulated Ack (C. Ingram-Smith, A. Guggisberg,
S. Henry, J. Welch, K. Laws, A. Mattison, A. Bizhanova, and K. Smith, manuscript in
preparation) or the presence of additional acetyl phosphate producing enzymes such as
Pox and Pta. Therefore, the control of ATP production by Ack in C. neoformans may
rest solely on the production of acetyl phosphate by Xfp.
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Non-phosphorylated PEP analogs were tested to determine the primary chemical
moiety that contributes to PEP allosteric inhibition for both L. plantarum Xfp and C.
neoformans Xfp2. Interestingly, pyruvate displayed no inhibition while glyoxylate,
which differs from pyruvate by the absence of a single methyl group, inhibits L.
plantarum Xfp more than PEP or OAA at the same concentration. Our results suggest
that PEP and OAA bind to the same or overlapping sites in both L. plantarum Xfp and C.
neoformans Xfp2, but glyoxylate binds at a distinct site.
Since glyoxylate is an allosteric inhibitor with presumably its own allosteric site
on both L. plantarum Xfp and C. neoformans Xfp2, there is likely a metabolic connection
between the presence of excess glyoxylate and the inhibition of Xfp, consequently
limiting the production of acetyl phosphate from X5P and F6P. The glyoxylate cycle
functions as a bypass of the decarboxylation steps of the tricarboxylic acid cycle allowing
for the use of simple two-carbon compounds, such as acetate and ethanol, to generate
malate from the combined action of the enzymes isocitrate lyase (Icl) and malate
synthase (Mls) (14-16). The glyoxylate cycle is utilized when glucose is limiting (14),
but the production of excess glyoxylate may indicate that other 2-carbon compounds,
such as acetate, are prevalent. Since we hypothesize that C. neoformans Xfp2 partners
with Ack to generate acetate and ATP, the presence of excess glyoxylate may indicate
that acetate is in abundance, so glyoxylate inhibits Xfp thereby inhibiting the production
of acetyl phosphate and consequently the production of acetate by Ack.
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We have failed to identify genes encoding the enzymes Icl and Mls within the L.
plantarum genome suggesting it lacks a glyoxylate cycle. However, L. plantarum cell
free extract is capable of metabolizing glyoxylate (17). An ORF within the L. plantarum
genome designated as 2-hydroxyacid dehydrogenase (Accession # YP_004888759) has
61% identity to a gene designated as a glyoxylate reductase (equation 5) in Lactobacillus
otakiensis, and it has also been shown in Rhizobium etli that an enzyme previously
labeled as 2-hydroxyacid dehydrogenase displays glyoxylate reductase activity (18).
glyoxylate + NAD(P)H ↔ glycolate + NAD(P)+

(5)

In plants, glyoxylate reductase is believed to function as a way of removing excess
reducing equivalents like NADPH (19), and glyoxylate reductase in L. plantarum could
serve a similar purpose. A possible connection between L. plantarum Xfp inhibition by
excess glyoxylate is that the presence of glyoxylate could indicate the presence of excess
NADPH. The pentose phosphate pathway (PPP) serves as a major source of the NADPH
produced in the cell. Thus, inhibiting Xfp, which utilizes PPP end products, may hinder
the PPP from producing additional end products thereby also reducing the amount of
NADPH produced upstream. The regulation of Xfp by glyoxylate in L. plantarum may
serve as a means of balancing the production and utilization of NADPH by the PPP and
glyoxylate reductase respectively to aid in cellular redox balance.

87

Concluding Remarks
Substrate cooperativity and allosteric regulation can no longer be considered a
purely eukaryotic Xfp phenomenon with the discovery of its existence in at least some
bacterial Xfps, specifically L. plantarum Xfp.

However, there are differences between

the degree of substrate cooperativity and the allosteric effectors that inhibit or activate
eukaryotic Xfp and bacterial Xfp from C. neoformans and L. plantarum respectively.
Both C. neoformans Xfp2 and L. plantarum Xfp share PEP, OAA and glyoxylate as
allosteric inhibitors, but C. neoformans Xfp2 is also inhibited by ATP and activated by
AMP while an activator of L. plantarum Xfp has yet to be discovered. Tighter regulation
of Xfp by ATP:AMP ratios may have evolved for eukaryotic Xfps due to the lack of
additional partner enzymes, compared to bacteria, that generate acetyl phosphate as a
substrate for Ack. Additionally, regulation by glyoxylate appears to result from different
phenomenon in C. neoformans that primarily produces glyoxylate through the glyoxylate
cycle versus L. plantarum which appears to lack a glyoxylate cycle. The presence of
allosteric regulation for both bacterial and eukaryotic Xfps suggests the production and
utilization of acetyl phosphate is important under different environmental stresses that
ultimately influence cellular metabolism.
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TABLE 3.1. Apparent kinetic parameters for L. plantarum Xfp and C. neoformans
Xfp2.
app

app

-1

kcat /K0.5

K0.5 (mM)

kcat

11.0 ± 1.4
1.0 ± 0.1

1.05 ± 0.05
1.12 ± 0.03

0.10 ± 0.01
1.11 ± 0.09

0.99 ± 0.04
0.68 ± 0.02

15.9 ± 1.3
3.47 ± 0.10
13.3 ± 1.5
4.22 ± 0.13
*
Previously reported kinetic parameters (6).

0.22 ± 0.01
0.32 ± 0.03

1.41 ± 0.11
0.59 ± 0.03

Substrate
L. plantarum
Xfp
C. neoformans
Xfp2*

F6P
Pi
F6P
Pi
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(sec )

-1

-1

H

(sec mM )

TABLE 3.2. Half maximal inhibitory concentrations (IC50s)

Enzyme

L. plantarum
Xfp

Inhibitor (Varied)

Inhibitor (Constant)

IC50 (mM)

Glyoxylate

--------

1.93 ± 0.05

-------OAA (10.5 mM)
Glyoxylate (2 mM)
-------Glyoxylate (2 mM)
--------

6.70 ± 0.12
1.14 ± 0.12
6.04 ± 0.11
10.5 ± 0.07
7.78 ± 0.20
4.93 ± 0.04

PEP (8 mM)

3.13 ± 0.18

--------

5.31 ± 0.13

Glyoxylate (5 mM)

4.01 ± 0.07

PEP

OAA
Glyoxylate
C. neoformans
Xfp2
PEP
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FIG 3.1. Effect of pH on L. plantarum Xfp and C. neoformans Xfp2 percent activity.
Enzyme reactions were performed using F6P and Pi K0.5 concentrations for L. plantarum
Xfp (■) and C. neoformans Xfp2 (●). Activity begins to decrease at pH values above 6.0
for C. neoformans Xfp2 and above 6.5 for L. plantarum Xfp.
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FIG 3.2. Effect of various ligands on L. plantarum Xfp activity. Reactions were
performed using L. plantarum Xfp F6P and Pi K0.5 substrate concentrations. Two
concentrations of each coenzyme or metabolic intermediate were tested. Reactions were
performed in triplicate. Activity is reported as percentage of activity with no ligand
present.
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FIG. 3.3. Effect of non-phosphorylated
phosphorylated PEP analogs on L. plantarum Xfp (A) and C.
neoformans Xfp2 (B) activity. Reactions were performed using L. plantarum Xfp F6P
and Pi K0.5 substrate concentrations. Concentrations of 8 mM (dark grey) and 16 mM
(light grey) for each non-phosphorylated
phosphorylated PEP analog were tested in triplicate. Activity is
reported as a percentage of activity with no ligand present.
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FIG 3.4. Inhibition of L. plantarum Xfp by OAA, PEP and glyoxylate. Reactions
were performed in triplicate using L. plantarum Xfp F6P and Pi K0.5 substrate
concentrations. Activity was measured in the presence of increasing concentrations of
OAA (A), glyoxylate (B) or PEP (C) and reported as a percentage of maximal activity
with no ligand presence.
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FIG 3.5.
5. Effect of PEP on L. plantarum Xfp substrate progress curves. Progress
curves were generated in the presence of 0 mM ((●), 8 mM (■), and 16 mM (♦
♦) PEP for
the substrates Pi (a) and F6P (b). Reactions were performed in triplicate and activities
were reported as µmol of product formed.
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CHAPTER 4
INVESTIGATIONS INTO THE LOCATION OF C. NEOFORMANS XFP2
ALLOSTERIC SITES THROUGH COMPUTATIONAL MODELING
AND SITE-DIRECTED MUTAGENESIS

Katie Glenn and Kerry Smith

I. ABSTRACT

Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) catalyzes the
reaction converting xylulose 5-phosphate (X5P) or fructose 6-phosphate (F6P) to acetyl
phosphate and glyceraldehyde 3-phosphate (G3P) or erythrose 4-phosphate (E4P)
respectively. Recently we have determined that at least some fungal and bacterial Xfps
are allosteric enzymes. Both Cryptococcus neoformans Xfp2 and Lactobacillus
plantarum Xfp are inhibited by phosphoenolpyruvate (PEP), oxaloacetic acid (OAA), and
glyoxylate, and PEP and OAA appear to share the same or possess overlapping sites on
both Xfps. The C. neoformans Xfp2 is also inhibited by ATP and activated by AMP, but
the L. plantarum enzyme is unaffected by these ligands. Additional studies provide
evidence that ATP inhibition of C. neoformans Xfp2 may be dependent on ATP
hydrolysis. Currently the only crystal structures that exist of Xfp are from two bacteria,
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Bifidobacterium breve and Bifidobacterium longum. Here we describe the generation of
both a monomer and dimer model of C. neoformans Xfp2 using the existing bacterial Xfp
crystal structures. The models were used to identify possible allosteric binding sites, and
ligand docking simulations were performed using PEP and OAA in an attempt to
discover the location of the PEP/OAA allosteric site. Residues predicted to form
hydrogen bonds with PEP and OAA were altered to the neutral residue alanine or amino
acids of opposite charge, but these alterations have yet to define the PEP/OAA pocket(s).
Also we discovered that AMP functions as a very potent enzyme activator capable of
rescuing activity of enzyme variants displaying much lower activity than wild type.
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II. INTRODUCTION

Xylulose 5-phosphate/ fructose 6-phosphate phosphoketolase (Xfp) is a thiamine
pyrophosphate (TPP) dependent enzyme that catalyzes the conversion of xylulose 5phosphate (X5P, EC 4.1.2.9; X5P + Pi → acetyl phosphate + glyceraldehyde 3phosphate) or fructose 6-phosphate (F6P, EC 4.1.2.22; F6P + Pi → acetyl phosphate +
erythrose 4-phosphate) to acetyl phosphate. Originally identified and characterized in
bacteria (1-4), Xfp has more recently been found in euascomycete and basidiomycete
fungi as well (5). Phylogenetic analysis show that fungal Xfps separate into two distinct
clades designated as XFP1 and XFP2 (A. Guggisberg and K. Smith, unpublished data).
All fungi in which an acetate kinase (ACK) open reading frame (ORF) has been identified
also have an XFP ORF (5). Therefore, as in certain bacteria, Xfp is believed to partner
with Ack (EC 2.7.2.1; acetyl phosphate + ADP ↔ acetate + ATP) in fungi as part of a
modified pentose phosphate pathway to generate acetate and ATP from pentose
phosphate pathway product X5P and F6P via formation of acetyl phosphate.
We purified and characterized the first eukaryotic Xfp, Cryptococcus neoformans
Xfp2 (Accession # CNAG_06923.7) (6). Unlike previously characterized bacterial Xfp
enzymes (1-4), C. neoformans Xfp2 displayed both substrate cooperativity (positive
cooperativity in regards to F6P binding and negative cooperativity for Pi binding) and
allosteric regulation. C. neoformans Xfp2 activity was inhibited by ATP,
phosphenolpyruvate (PEP), oxaloacetic acid (OAA), (6) and glyoxylate (K. Glenn and K.

101

Smith, in revision) and activated by AMP (6). Previous kinetic characterizations of Xfp
from bacteria do not report the presence of either substrate cooperativity or allosteric
regulation for these enzymes (1-4). Recently, we purified and demonstrated that the
Lactobacillus plantarum Xfp, initially characterized by Yevenes et al. (2), displayed both
substrate cooperativity and allosteric regulation. We found that L. plantarum Xfp is an
allosteric enzyme inhibited by PEP, OAA and glyoxylate but unaffected by ATP and
AMP; and this enzyme also exhibits negative cooperativity for Pi (K. Glenn and K.
Smith, in revision).
Currently, the structures of Bifidobacterium breve (3) and Bifidobacterium
longum (7) Xfp enzymes have been solved. Analysis of these structures show that the
Xfp monomer consists of 3 domains, the N-terminal (PP) domain, the Middle (Pyr)
domain and the C-terminal domain, with the active site located between the PP and Pyr
domains (3,7). Both structures support the ping pong bi bi reaction mechanism originally
proposed by Yevenes et al. (2,3,7). Even though neither B. breve nor B. longum Xfp
have been reported to be allosterically regulated, our studies have shown that at least one
bacterial Xfp, L. plantarum Xfp, is an allosteric enzyme (K. Glenn and K. Smith, in
revision). Here we describe the generation of a C. neoformans Xfp2 model from the
existing B. breve and B. longum Xfp crystal structures. Since both a bacterial Xfp and C.
neoformans Xfp are allosterically regulated by PEP and OAA at a shared or overlapping
site (K. Glenn and K. Smith, in revision), we performed ligand docking simulations to
attempt to determine the location of C. neoformans Xfp2 allosteric binding sites,
primarily focusing on the PEP/OAA binding site.
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III. MATERIALS AND METHODS

Materials
All chemicals were purchased from VWR, Fisher Scientific, or Sigma Aldrich.
Oligonucleotides for site-directed mutagenesis were purchased from Integrated DNA
Technologies.
Molecular Modeling
All modeling was performed using Accelrys Discovery Studio 3.5 software. The
C. neoformans Xfp2 monomer model was built from the aligned and superimposed
template structures of both B. breve (PDB ID 3AHC) and B. longum (PDB ID 3AI7) Xfp
downloaded from RSCB Protein Data Bank (PDB). The C. neoformans Xfp2 homodimer
model was built from the B. longum Xfp structure (PDB ID 3AI7). The monomer and
homodimer model with the lowest Discrete Optimized Protein Energy (DOPE) score
were chosen for further analysis. Models were prepared prior to use by other software
applications using the Automatic Preparation function that prepares the protein by
inserting missing atoms, modeling missing loops, removing water molecules and
protonating residues based on a pH of 5.5, at which maximal C. neoformans Xfp2
activity occurs. Possible allosteric binding sites were determined by first identifying all
possible cavities on the Xfp2 model using the Define and Edit Binding Sites From
Receptor Cavities function. Ligand docking simulations were then performed for a
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specified ligand using the software’s LibDOCK function that docks ligands within a site
based on the ligand’s interaction with polar and apolar regions within that site.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed on the codon-optimized C. neoformans
Xfp2 gene using the QuikChange site-directed mutagenesis kit (Agilent Technologies,
Inc.) to alter residues predicted to interact with ligands within proposed ligand binding
sites of the Xfp2 model. Mutagenic primers were approximately 40 nucleotides in length
with the altered base located in the center of the sequence. Mutagenesis was confirmed
by Sanger-style sequencing at the Clemson University Genomics Institute.
Production and Purification of C. neoformans Xfp2 Variants
Confirmed Xfp2 variants were produced in the Eschericia coli expression strain
RosettaBlue™ (Novagen) grown in LB medium supplemented with 1 % dextrose, 50
µg/mL ampicillin, and 34 µg/mL chloramphenicol. At an absorbance of ~0.8 at 600 nm,
IPTG was added to a final concentration of 1 mM to induce production of the enzyme.
Expression was allowed to proceed overnight at room temperature, and cells were
harvested by centrifugation. C. neoformans Xfp2 variants were purified as previously
described for wild type C. neoformans Xfp2 (6).
Enzymatic Assays for Xfp2 Activity
C. neoformans Xfp2 activity was determined by measuring the production of
acetyl phosphate using a modified hydroxamate assay previously described (6,8). 200 µL
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standard reaction mixtures were prepared as previously described (6), and only F6P and
sodium phosphate pH 5.5 were used as substrates due to the lack of commercial
availability of X5P. Reactions were initiated by the addition of enzyme and allowed to
proceed for 30 minutes at 40°C. Afterwards, 100 µL of 2M hydroxylamine HCl (pH 7.0)
was added to each reaction, and the reactions were allowed to incubate at room
temperature for 10 minutes to convert all acetyl phosphate to acetyl hydroxamate.
Finally, reactions were terminated by the addition of 600 µL of a 50:50 mixture of 2.5 %
FeCl3 in 2N HCl and 10 % trichloroacetic acid to generate the ferric hydroxamate
complex that was measured spectrophotometrically at 540 nm. Most initial tests of
variant activity in the presence and absence of both PEP and AMP were performed in
singlet trials. The R66A variant full kinetic analysis and all ATP hydrolysis experiments
were performed in triplicate.
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IV. RESULTS

Generation of C. neoformans Xfp2 monomer model
The C. neoformans Xfp2 monomer model (Figure 4.1) was built from the
monomer structures of both B. breve and B. longum Xfp using Accelrys Discovery Studio
3.5 software. Like the B. breve and B. longum Xfp, the C. neoformans Xfp2 monomer
consists of an N-terminal PP (blue), middle Pyr (white) and C-terminal (red) domain.
The Define Binding Site from Receptor Cavities function was performed and located a
total of 44 possible binding sites on the C. neoformans Xfp2 model. Ligand docking
simulations showed that TPP binds to site 5 on the model which overlaps well with the
TPP binding sites of B. breve (3) and B. longum Xfp (7). Therefore, site 5 (labeled with a
red circle in Figure 4.1) is considered to be the location of the C. neoformans Xfp2 active
site.
Investigations into the location of the C. neoformans Xfp2 PEP/OAA allosteric site
based on bonds formed between ligand and evolutionarily conserved residues
The PEP and OAA molecule structures were imported into Discovery Studio 3.5
software and docked into each of the 44 possible binding sites using the LibDock
function. Both PEP and OAA were successfully docked into many of the sites. Since
PEP and OAA have been demonstrated to be allosteric effectors for the bacterial L.
plantarum Xfp (K. Glenn and K. Smith, in revision) and the eukaryotic C. neoformans
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Xfp2 (6), we hypothesize that this site may be evolutionarily conserved among both
bacterial and eukaryotic Xfps. Therefore, we attempted to narrow down the number of
candidate PEP/OAA binding sites by focusing on sites in which both PEP and OAA can
bind and directly interact, through hydrogen bonding, with several evolutionarily
conserved residues within that site. ConSurf server was used to determine if a residue is
evolutionarily conserved (9,10). The ConSurf server first searches for sequences
homologous to the sequence of interest and then uses multi-sequence alignment, existing
structures, and phylogenetic analysis to assign residues in the input sequence a score of 1
to 9, with a score of 9 assigned to residues that are considered to be highly conserved.
Utilizing the methodology outlined above we identified two sites, site 13 and site
35, as PEP/OAA binding site candidates. The position of these sites on the C.
neoformans Xfp2 monomer model (Figure 4.2), along with 2D diagrams that represent
one of several positions in which PEP can bind within each site. In both site 13 and site
35, PEP and OAA hydrogen bond with two evolutionarily conserved residues (ConSurf
scores of 8 or 9). Site-directed mutagenesis was performed to generate the individual
variants R66A and K64A in site 13 and D547K and K602A in site 35 because these
residues had high ConSurf scores and were predicted to directly interact with PEP and
OAA by forming hydrogen bonds. All residues for which mutagenesis was performed
are listed in Table 4.1 along with their ConSurf scores and binding site location.
The C. neoformans Xfp2 R66A variant was the only variant active enough to
perform a full kinetic analysis (Table 4.2). Alteration of Arg66 to Ala primarily reduced
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the overall enzyme activity demonstrated by a much lower kcatapp compared to wild type
(WT) C. neoformans Xfp2. The R66A variant has similar K0.5 values to those of the WT
and also retains both positive cooperativity (h>1) for F6P and negative cooperativity
(h<1) for Pi (Table 4.2). Since the R66A variant was generated due to its possible
interactions with PEP within a proposed PEP/OAA binding site, PEP was added to the
reaction mix to determine if activity of this variant is still inhibited by the presence of
PEP. All previous studies involving allosteric inhibitors have been performed using K0.5
substrate concentrations. At K0.5 concentrations for both substrates, the activity of the
R66A variant is only around 0.027 µmol of product formed per 30 minute reaction. In
the presence of 8 mM PEP, R66A activity decreases from 0.027 µmol to 0.012 µmol of
product formed per 30 minute reaction. Therefore, PEP still inhibits R66A activity, but it
is difficult to compare PEP’s effect on R66A to WT C. neoformans Xfp2 at similar
concentrations when the activity of the R66A variant is very low.
AMP acts as a very potent enzyme activator/stabilizer
In an attempt to increase R66A variant activity, varying amounts of AMP, the
only known C. neoformans Xfp2 activator (6), was added to the reaction assay. As
expected, like with the WT, AMP was able to increase activity of the R66A variant
(Figure 4.3). Surprisingly, the addition of AMP was able to rescue R66A activity back to
WT levels. Upon the addition of 2 mM AMP, R66A activity reaches 100% WT activity
of the same enzyme concentration. Since AMP boosts R66A activity, PEP inhibition was
tested in presence of AMP (Figure 4.4). The effect of the presence and absence of 8 mM
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PEP on R66A activity was tested on reactions containing 0.02, 0.2 and 0.5 mM AMP. As
shown in Figure 4.4, 8 mM PEP inhibits activity in the presence of all three
concentrations of AMP suggesting that R66A is not involved in the binding of PEP.
To better understand why the R66A alteration drastically reduces enzyme activity
and how AMP is capable of overcoming the effects of this mutation, a model was
generated of the R66A variant using the Build Mutant function of the Discovery Studio
3.5 software. Figure 4.5 shows an overlay of the WT C. neoformans Xfp2 model and the
R66A variant focused on the R66 residue with a red sphere marking the active site. The
R66 residue is in close proximity to the active site, and therefore, may even be involved
in active site mechanisms such as substrate binding or stabilizing reaction intermediates.
Additionally the R66A variant is predicted to produce several structural changes,
indicated by green arrows in Figure 4.5, that are also in close proximity to the active site.
Therefore the R66A model suggests that the reduction in enzyme activity may be due to
changes in the enzyme active site but does not provide insight as to how AMP is able to
overcome such structural alterations.
C. neoformans Xfp2 is known to have optimal activity at lower pH, and activity
decreases as pH approaches neutrality. Therefore, the effect of AMP on C. neoformans
Xfp2 activity in the presence of increasing pH was tested. It was found that AMP can
increase WT activity at K0.5 substrate concentrations at elevated pH values (Figure 4.6).
The addition of 0.5 mM AMP can increase Xfp2 activity by approximately 8-fold at pH
7.0.
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Investigations into the location of the C. neoformans Xfp2 PEP/OAA allosteric site
based on bonds formed between ligand and arginine residues
Utilizing PDBeMotif version 2.0c, an online service that searches the Protein
Data Bank with respect to protein motifs (11), it was discovered that PEP often directly
interacts and binds with arginine residues in protein active sites. Therefore, all of the
putative binding sites of the C. neoformans Xfp2 model were explored to locate sites in
which PEP could interact with an arginine residue. There are five sites (Figure 4.7) in
which PEP is predicted to bind and interact with an arginine residue. Two of these sites,
site 10 and site 14, overlap, and PEP is predicted to interact with the same arginine
residue, Arg571. The four arginine residues, their ConSurf scores, the mutations
generated, and binding site location are listed in Table 4.1.
Both R300A and R55A variants were active in the absence of the activator AMP
but activity was roughly 25% lower than WT at the same concentration for R55A and
75% lower for R300A. Both variants displayed activation in the presence of 0.5 mM
AMP and inhibition in the presence of 8 mM PEP. Therefore, neither residue appears to
be involved in PEP binding. Purified R571A and R753A had very low concentrations (~
0.3 mg/mL) after column purification. Both variants showed no activity for R753A and
very little activity for R571A (~0.034 µmol of product formed per 30 minute reaction).
However, the addition of 0.5 mM AMP resulted in some activity from R753A variant (~
0.04 µmol of product per 30 minute reaction), but this activity was inhibited by the
addition of 8 mM PEP. Interestingly addition of 0.5 mM AMP did not increase R571A
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activity, but the little activity observed for this variant was inhibited by 8 mM PEP.
Based on these findings it appears that neither R571 nor R753 are involved in PEP
binding, however additional tests are needed to rule them out with any certainty.
Generation of C. neoformans Xfp2 dimer structure
The functional unit of both B. breve and B. longum Xfp is a dimer. However the
only Xfp dimer structure available in PDB is that of B. longum. Therefore, the C.
neoformans Xfp2 dimer model (Figure 4.8) was built from the dimer structure of B.
longum Xfp only. The C. neoformans Xfp2 dimer model consists of two active sites still
located between the N-terminal and middle domains of each monomer. However it has
been shown that residues from both subunits comprise each active site of the B. longum
Xfp (7), and this is most likely the case for C. neoformans Xfp2 as well. Therefore, it is
possible that allosteric sites may consist of residues from both monomers.
ATP Inhibition may be dependent on ATP hydrolysis
Since the C. neoformans Xfp2 model was built from bacterial Xfps, the search for
allosteric binding sites using this model has thus far centered on identifying the
PEP/OAA binding sites known to exist for at least one bacterial Xfps (K. Glenn and K.
Smith, in revision). Therefore, the model may not be relevant in determining the location
of the ATP or AMP site because neither of these effectors allosterically affect bacterial
Xfp activity. However, a non-hydrolyzable ATP analog, β,γ-methyleneadenosine 5′triphosphate (AMP-PCP), was used to learn more about the mechanism of ATP
inhibition, and to determine if it is dependent on the hydrolysis of ATP.
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Unlike ATP, AMP-PCP does not inhibit C. neoformans Xfp2 (Figure 4.9). More
interestingly, AMP-PCP resulted in slightly elevated activity compared to activity when
no effector is present. Adenosine was tested to see if inhibition is dependent on the
adenosine portion of ATP, but adenosine alone does not appear to contribute to
inhibition. These results suggest that ATP hydrolysis may be an important factor in ATP
inhibition of C. neoformans Xfp2. Since AMP-PCP shows slight elevation of WT
activity, the effect of AMP-PCP at both pH 5.5 and pH 7.0 was tested to determine if
AMP-PCP mimics AMP’s ability to enhance Xfp2 activity at elevated pH. AMP-PCP can
enhance WT activity at elevated pH but not to the level observed with AMP (Figure
4.10). Additionally, AMP-PCP and ATP were both added to the reaction to determine if
AMP-PCP can rescue ATP inhibition. Reactions containing both AMP-PCP and ATP
display intermediate activity between that of ATP and AMP-PCP presence alone (Figure
4.11) which may suggest competitive binding between both molecules to occupy the
allosteric site.
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V. DISCUSSION

We have recently shown that at least some Xfp enzymes from both bacteria (K.
Glenn and K. Smith, in revision) and fungi (6) are allosterically regulated. Both L.
plantarum Xfp and C. neoformans Xfp2 are inhibited by PEP, OAA and glyoxylate, and
PEP and OAA appear to share the same or possess overlapping allosteric sites. Here we
attempt to locate the PEP/OAA allosteric site through ligand docking simulations using a
C. neoformans Xfp2 model built from known bacterial Xfp crystal structures from B.
breve (3) and B. longum (7). Like with B. breve and B. longum Xfp, the C. neoformans
Xfp2 model shows the active site to be located between the N-terminal (PP) domain and
the middle (PYR) domain. The software’s Define and Edit Binding Site feature located a
total of 44 possible binding sites on the Xfp2 model. Sites were narrowed down using
two different methodologies. The first method involved focusing on sites in which both
PEP and OAA docked and formed bonds with residues deemed to be evolutionarily
conserved due to their high ConSurf scores (9,10). The second method involved focusing
on sites in which docked PEP interacted with arginine residues, as a search of the
PDBeMotif database (11) showed that PEP often forms bonds with arginine residues
within active sites.
Two possible PEP/OAA binding sites, site 13 and site 35 were first chosen due to
their ability to potentially bind both PEP and OAA such that bonds were formed between
the ligand and Xfp2 residues having high ConSurf scores. Except for the R66A variant,
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most of the Xfp2 variants purified were not highly concentrated, so a full kinetic analysis
was performed only on the R66A variant. The R66A alteration primarily caused a
dramatic decrease in turnover number, kcat, compared to WT Xfp2. AMP was added to
the R66A reaction mix in an attempt to boost activity for PEP inhibition analysis, but
surprisingly, AMP at a concentration of 2 mM was capable of rescuing R66A activity up
to WT values (Figure 4.3). The R66 residue is located very close to the Xfp2 active site
(Figure 4.5). Therefore, it is possible that R66 may play a role in active site reaction
mechanism. In fact generating the R66A alteration using the Build Mutant Function of
Discovery Studio 3.5 software shows some structural alterations in regions of the protein
located close to the active site (Figure 4.5). However it remains unclear as to how AMP
is able to override the structural changes induced by the R66A alteration. We
hypothesize that the binding of AMP stabilizes the active R state form of the enzyme
over the less active T state form. It is possible that if R66A variant destabilizes the active
site then AMP’s ability to induce the R state may be why AMP can completely override
this amino acid change. In addition to being capable of circumventing enzyme alterations
induced by amino acid changes, AMP is capable of drastically increasing C. neoformans
Xfp2 activity at elevated pH. The ability of AMP to induce a conformational change that
overrides the changes caused by a residue alteration or elevated pH shows that AMP is a
much stronger activator than previously thought. However as the R66A variant is still
inhibited by PEP even in the presence of AMP, this residue does not appear to be
involved in PEP binding. Additionally the K602A variant from site 35 displayed some
activity in the presence of AMP that was also inhibited by the presence of PEP.
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Therefore, we found no evidence suggesting either site 13 or sites 35 as part of a
PEP/OAA binding site.
We vitalized a second approach to identify the PEP/OAA binding site by focusing
on sites in which PEP forms hydrogen bonds with the side chain of arginine residues. A
search of the Protein Data Bank using PDBeMotif revealed that PEP often forms bonds
with arginine residues within active sites. Therefore, all arginine residues predicted to
interact with PEP through ligand docking simulations were altered. All four arginine
variants displayed reduced enzyme activity; however, the activity was still inhibited by
the presence of PEP suggesting that these residues are not essential for PEP binding.
Additionally three of the four variants were activated by AMP; however, there was no
increase in R571A variant activity in the presence of AMP. Therefore, it is possible that
R571A may be involved in AMP binding. The R571 residue on the C. neoformans Xfp2
dimer model (Figure 4.12) is not near the active sites nor is it located near junctions
between both monomers to form the dimer suggesting it is not involved in either the
active site mechanism or in subunit oligomerization. The location of R571 on the Cterminal domain lends support to a possible involvement in allosteric effector binding
since it has been suggested that the C-terminal domain of the phosphoketolase related
enzyme transketolase may serve as a binding site for regulatory molecules (12). For now
it is difficult to determine the role that R571 plays in the Xfp2 structure because activity
and concentration of the R571A variant were very low. Future studies involving this
variant will be dependent on the purification of additional, more concentrated enzyme.
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There is no evidence that C. neoformans Xfp2 inhibition by ATP is dependent
upon ATP hydrolysis based on the absence of a Walker motif (13) within the Xfp2
sequence. However, the effects of non-hydrolyzable ATP on Xfp2 activity were still
investigated. The presence of the non-hydrolyzable ATP analog, AMP-PCP, did not
inhibit C. neformans Xfp2 activity and actually resulted in slightly elevated activity
compared to the absence of any effector. This result suggests that ATP inhibition is
dependent upon ATP hydrolysis. Alternatively, AMP-PCP may actually mimic the
binding of AMP rather than ATP, which would explain the slight increase in activity
compared to activity in the absence of effector. Since AMP is capable of increasing C.
neoformans Xfp2 activity at elevated pH, the effect of AMP-PCP on Xfp2 activity was
tested at both pH 5.5 and pH 7.0. AMP-PCP stimulated Xfp2 activity but the stimulation
was much lower than that of AMP, especially at pH 7.0. When both AMP-PCP and ATP
are present, activity is intermediate to that of ATP or AMP-PCP present alone, suggesting
that ATP and AMP-PCP do compete for the same allosteric site. Additional studies are
required to determine if ATP inhibition is truly dependent on ATP hydrolysis.
In conclusion, the sites we identified in the C. neoformans Xfp2 monomer model
proved not to be the PEP/OAA binding site. However, other potential allosteric sites
remain to be explored. Phosphofructokinase (Pfk), the principle regulatory enzyme of
glycolysis, is one of the most well studied allosteric enzymes (14). The primary allosteric
effectors of Pfk are ADP, which functions as an activator, and PEP, which functions as an
inhibitor. Structural studies of Pfk from B. stearothermophilus show that PEP and ADP
both bind at a single site located at the interface between tetrameric subunits but induce
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very different conformational changes (14,15). Therefore, it may be worthwhile to
continue the search for C. neoformans Xfp2 allosteric effector sites using the dimer
model, focusing on sites between subunits. We have recently shown that the bacterial
Xfp from L. plantarum is not regulated by ATP and AMP, the primary inhibitor and
activator of C. neoformans Xfp2 respectively (K. Glenn and K. Smith, in revision). Since
the C. neoformans Xfp2 model was built from bacterial Xfp structures, this model is less
likely to be relevant in identifying the binding sites of AMP and ATP. However, initial
ligand docking simulations showed that ATP can bind in only a few predicted sites on the
C. neoformans Xfp2 monomer, but additional binding sites will likely be revealed
through ligand docking simulations with the dimer model. Our preliminary studies
suggest that ATP inhibition may even be dependent upon ATP hydrolysis as C.
neoformans Xfp2 is not inhibited by the non-hydrolyzable ATP analog AMP-PCP.
AMP-PCP instead caused slight enzyme activation, suggesting that AMP-PCP may
mimic AMP binding. However, we also saw evidence consistent with competitive
binding between ATP and AMP-PCP for the ATP allosteric site (Figure 4.11). The
AMP-PCP binding data also supports the idea of a single binding site for AMP and ATP,
much like the ADP/PEP effector site of Pfk. Continued studies of the C. neoformans
Xfp2 monomer and dimer models should reveal more information regarding the
mechanisms of Xfp allosteric regulation and the location of these allosteric binding sites.
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TABLE 4.1. C. neoformans Xfp2 enzyme variants.
Residue
ConSurf score
Variant
Binding Site
R66
8, e, f
R66A
13
K64
9, e, f
K64A
13
D547
9, e, f
D547K
35
K602
9, e, f
K602A
35
R571
9, b, s
R571A
10 & 14
R753
9, e, f
R753A
30
R55
2, e
R55A
17
R300
8, e, f
R300A
24
ConSurf assigns scores1-9 with 9 corresponding to a highly conserved residue along with
the following descriptors e = exposed, b = buried, f = functional, and/ or s = structural
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TABLE 4.2. Apparent kinetic parameters for C. neoformans Xfp2 R66A variant
app

Substrate K0.5 (mM)
C. neoformans
Xfp2 R66A

F6P
Pi

26.7 ± 1.0
17.1 ± 2.6

kcat

app

-1

(sec )

0.063 ± 0.003
0.055 ± 0.005

H
-1
-1
(sec mM )
0.0024 ± 0.0001 2.14 ± 0.27
0.0032 ± 0.0003 0.75 ± 0.05

15.9 ± 1.3 3.47 ± 0.10
0.22 ± 0.01
13.3 ± 1.5 4.22 ± 0.13
0.32 ± 0.03
WT – wild type, *Previously reported kinetic parameters (6).
C. neoformans
Xfp2 WT*

F6P
Pi

kcat /K0.5
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1.41 ± 0.11
0.59 ± 0.03

FIG 4.1. Model of C. neoformans Xfp2 monomer. Model was generated using both
the B. breve and B. longum Xfp crystal structures. Model colored from N-terminal (blue)
to C-terminal (red). Active site (area where TPP binds) is marked by a transparent red
sphere.
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FIG 4.2. Location of the predicted PEP binding sites 13 and 35. Red spheres mark
the location of sites 13, 35 and the active site on the C. neoformans Xfp2 monomer
model. 2D diagrams depict one of several possible poses PEP can take in each site.
Hydrogen bonds between PEP and site residues are indicated by green (hydrogen bond
with amino acid main chain) and blue (hydrogen bond with amino acid side chain) arrows
that point towards the electron donor.
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FIG 4.3. AMP activation of C. neoformans Xfp2 R66A variant. Reactions were
performed in triplicate for C. neoformans Xfp2 R66A variant using WT C. neoformans
Xfp2 F6P and Pi K0.5 concentrations in the presence of increasing amounts of AMP.
Activity was measured as a percentage of WT C. neoformans Xfp2 where activity with
no AMP at the same enzyme concentration as the R66A variant was set at 100%.
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FIG 4.4. Effect of PEP on C. neoformans Xfp2 R66A variant activity
ctivity in the presence
of AMP. Reactions were performed in singlet using wild type C. neoformans Xfp2 K0.5
substrate concentrations. Activity is reported as µmols
mols of product formed per 30 minute
reactions.
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FIG 4.5. Model predicting structural effects of R66A mutation. The wild type C.
neoformans Xfp2 model is in blue, and the R66A mutation model is in pink. R66 residue
is shown in yellow. The C. neoformans Xfp2 active site is marked by the red sphere.
Green arrows point to structural changes caused by the R66A mutation.
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FIG 4.6. Effect of pH on WT C. neoformans Xfp2 activity in the presence and
absence of AMP. Reactions were performed in triplicate using K0.5 substrate
concentrations, and activity is reported as µmol
mol of product formed per 30 minute
reaction. Wild type C. neoformans Xfp2 activity was measured as a function of
increasing pH in the presence of 0 mM AMP (red), 0.02 mM AMP (blue) and 0.5 mM
AMP (green).
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FIG 4.7. Location of sites on the C. neoformans Xfp2 model in which PEP interacts
i
with arginine residues. Sites 10, 14, 17, 24, and 30, labeled with arrows and marked by
red spheres on the C. neoformans Xfp2 monomer model, contain arginine residues that
through ligand docking simulations are predicted to interact with PEP.
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FIG 4.8. C. neoformans Xfp2 dimer model. Model generated from the B. longum Xfp
dimer structure. Colors indicate the N-terminal (blue) and C-terminal (red) domains.
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FIG 4.9. Effect of adenosine and AMP
AMP-PCP on C. neoformans Xfp2 activity
compared to ATP inhibition. Reactions
tions were performed in triplicate using K0.5
substrate concentrations of F6P and Pi. Activity is reported in percentage where 100% is
wild type activity
ctivity with no effector present
present.
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FIG 4.10. Effect of AMP-PCP
PCP on C. neoformans Xfp2 activity at pH 5.5 (grey) and
pH 7.0 (black). Reactions were performed in triplicate using K0.5 substrate
concentrations of F6P and Pi. Activity is reported as percentage where 100% is wild type
activity at pH 5.5 in the absence of effector.
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FIG 4.11 Effect of the presence of both AMP
AMP-PCP and ATP on C. neoformans Xfp2
activity. Reactions were performed in triplicate using K0.5 substrate concentrations of
F6P and Pi. Activity is reported in percent where 100% is wild type activity in the
absence of effector.
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FIG 4.12. Location of R571 residue on the C. neoformans Xfp2 dimer model. The
two large red spheres mark the two active sites of the Xfp2 dimer. The R
R571
571 residue is
colored green on one of the two monomers and yellow on the other.
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CHAPTER 5
CONCLUSIONS AND FUTURE WORKS

This dissertation describes the first characterization of a eukaryotic xylulose 5phosphate/ fructose 6-phosphate phosphoketolase (Xfp) from the pathogenic fungus
Cryptococcus neoformans. Xfp is believed to partner with acetate kinase (Ack) to
produce acetate during cryptococcal infection. Studies have shown that acetate is one of
the most abundant metabolites produced during cryptococcosis. In addition, Xfp and Ack
have been shown in several different studies to be expressed and/or upregulated in C.
neoformans during infection, and an Xfp2 homolog has been shown to be required for
full virulence in the insect fungal pathogen Metharizium anisopliae. If the Xfp-Ack
pathway does prove to be important during C. neoformans infection, this pathway could
be utilized as a possible drug target as these enzymes are not present in humans.
C. neoformans Xfp2 displayed substrate cooperativity in the form of positive
cooperativity for fructose 6-phosphate (F6P) and xylulose 5-phosphate (X5P) and
negative cooperativity for Pi. Additionally, C. neoformans Xfp2 was found to be an
allosteric enzyme inhibited by ATP, phosphoenolpyruvate (PEP), oxaloacetic acid
(OAA) and glyoxylate and activated by AMP. Studies showed that PEP and OAA share
the same or possess overlapping allosteric sites on the enzyme while ATP and glyoxylate
bind at separate sites. Regulation by AMP:ATP levels seem to support a partnership
between Xfp2 and Ack in producing acetate and ATP while inhibition by PEP, OAA, and
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glyoxylate seem to suggest an indirect connection between the Xfp-Ack pathway and
gluconeogenesis and the glyoxylate cycle respectively (Figure 5.1).
Even though bacterial Xfps have previously been characterized, there is no report
that any of these enzymes display either substrate cooperativity or allosteric regulation.
The Lactobacillus plantarum Xfp was purified and characterized specifically to
determine if this enzyme displayed substrate cooperativity or allosteric regulation. L.
plantrum Xfp displayed substrate cooperativity in the form of negative cooperativity for
Pi and was found to be an allosteric enzyme inhibited by PEP, OAA and glyoxylate but
unaffected by the primary C. neoformans Xfp2 allosteric effectors, ATP and AMP. Like
with C. neoformans Xfp2, PEP and OAA bind at the same or overlapping sites on L.
plantarum Xfp while glyoxylate binds at a separate site. This study provided the first
evidence that at least some bacterial Xfps are allosterically regulated.
To locate the C. neoformans Xfp2 allosteric sites, a model of this enzyme was
generated from the existing bacterial Xfp structures from Bifidobacterium breve and
Bifidobacterium longum. Ligand docking simulations were performed using PEP and
OAA within predicted binding sites. Several sites were investigated by performing sitedirected mutagenesis on residues predicted to directly interact with PEP and OAA. Each
variant generated was still inhibited by PEP suggesting that those residues, and most
likely those sites, are not involved in PEP binding. Even though these studies have yet to
reveal the location of the PEP/OAA binding sites, they have provided some interesting
insights into other aspects of C. neoformans Xfp2 regulation. For example, we
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discovered that AMP acts as a very potent activator. AMP was able to rescue at least
some activity for most variants that showed a considerable decrease in activity. AMP
was able to fully rescue activity of the R66A variant back up to wild type activity values.
However, one variant, R571A, showed no increase in activity in the presence of AMP.
Therefore it is possible that we have stumbled across a residue that is part of the AMP
allosteric site, but additional studies will be needed to show this. In addition, the
presence of AMP was able to overcome the decrease in C. neoformans Xfp2 activity that
occurs at elevated pH values. It is possible that AMP is capable of overcoming what are
typically adverse conditions, such as single amino acid mutations and elevated pH,
because it induces a very stable, active R state enzyme conformation. Additionally,
preliminary studies were performed using a non-hydrolyzable ATP to see if ATP
inhibition is dependent on ATP hydrolysis. The non-hydrolyzable ATP did not inhibit
the enzyme suggesting that inhibition by ATP may be dependent on ATP hydrolysis, but
additional experiments in this area are required to determine if this is true.
Future studies should focus on gaining a better understanding of C. neoformans
Xfp2 allosteric regulation. Ideally a crystal structure of C. neoformans Xfp2 in the
presence and absence of allosteric effectors will eventually be obtained. However, to
obtain a crystal structure, very pure, concentrated enzyme is required, and in my
experience, very little enzyme following purification. Future studies should focus on
ways to generate and purify more enzyme by using different expression vectors and
possibly a different expression system other than E. coli. Until a crystal structure of C.
neoformans Xfp2 is obtained, the models generated and described in this dissertation
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provide the best resource for exploring and identifying the location of allosteric sites.
However, studies utilizing the Xfp2 monomer structure have yet to reveal the location of
the PEP/OAA binding site. The recently obtained dimer model shows new binding sites
formed between both monomers. Therefore future studies should focus on new sites
within this Xfp2 dimer model. Also additional studies are necessary to determine if ATP
inhibition is dependent upon ATP hydrolysis as preliminary assays using a nonhydrolyzable ATP suggest. Future studies should involve radiolabeled ATP and thin
layer chromatography analysis to determine if ATP is hydrolyzed and converted to
labeled ADP by C. neoformans Xfp2 during inhibition.
These studies have revealed that at least some enzymes in the Xfp family from
both fungi and bacteria exhibit substrate cooperativity and are allosterically regulated.
The regulation of both L. plantarum Xfp and C. neoformans Xfp2 by different allosteric
effectors, suggests that this enzyme plays different roles in bacteria and fungi. However,
such tight regulation of Xfp by several different metabolic intermediates suggests that the
production of acetyl phosphate may be an important phenomenon in both bacteria and
fungi under various environmental conditions that ultimately influence cellular
metabolism.
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FIG 5.1. Model of how Xfp2 fits into C. neoformans cellular metabolism. Inhibitors
are labeled in red while activators are colored green.

139

APPENDIX
Appendix A
A MUTATION OF CRE1 IN MEDICAGO TRUNCATULA THAT SUPPRESSES
SUPERNODULATION AND ROOT GROWTH WITH MINIMAL EFFECT ON
CYTOKININ RESPONSES
Elise L. Schnabel, Tessema K. Kassaw, Katie F. Glenn, Kerry S. Smith
and Julia A. Frugoli

MATERIALS AND METHODS
Molecular Modeling
Discovery Studio 3.5 software (Accelrys, Inc.) was used to generate a model of
the wild type M. truncatula cytokinin receptor sensor domain (MtCRE1) based on the
Arabidopsis thaliana histidine kinase 4 (AHK4) complexed with N6-isopentenyladenine
(accession code 3T4J) from Hothorn, et al. (2011). The MtCRE1 V97I variant model was
generated using the software’s Build Mutant function that creates an alteration at the
specified residue and optimizes conformation of the mutated and surrounding residues.
For both the wild type and V971 variant, the model with the lowest DOPE (Discrete
Optimized Protein Energy) score was chosen for further analysis. The Define and Edit
Binding Sites From Receptor Cavities function was used to determine the active site for
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both the wild type and variant model and the site that overlaid best with the active site of
AHK4 was chosen for ligand docking simulations. Ligand docking of the cytokinin
ligand N6-isopentenyladenine within the active sites of both the MtCRE1 wild type and
MtCRE1 V97I variant models was performed using the Dock Ligands function that
docks ligands within a site based on the ligand’s interaction with polar and apolar regions
within that site.
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RESULTS

A model of the membrane external portions of wild type MtCRE1 was generated
from AHK4 using Accelrys Discovery Studio 3.5 software (Figure 1a). The loop (amino
acids 95-108) containing V97 is positioned distinct from the MtCRE1 ligand binding site
(Figure 1a). Alteration of V at position 97 to I (the cre1-4 defect) does not affect
positioning of surrounding residues, and inspection of the overall structures did not reveal
any major structural changes between wild type MtCRE1 and the V97I variant, however,
the side chain of the amino acid now rotates outward from the loop (Figure 1b). Ligand
docking simulations of N6-isopentenyladenine within the active site were performed for
both the wild type and variant models to determine if the V97I mutation affected
cytokinin binding. These ligand docking simulations did not reveal any differences
between the WT and V97I variant in primary hydrogen bonding residues between N6isopentenyladenine and active site amino acids residues (data not shown).
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Figure A.1 The amino acid change in the cre1-4 mutant does not affect the
cytokinin binding pocket (a) Ribbon diagram of the predicted tertiary structure of the
sensor domain dimer of MtCRE1 complexed with 2iP (yellow) based on the crystal
structure of AHK4 (see Materials & Methods). Amino acids altered in sensor domain
mutants are shown in purple (Ljsnf2, Mtcre1-4, and Atwol-1). The Mtcre1-4 mutation
resides in a region distal to the cytokinin binding pocket highlighted in red. (b) Close up
of red region in (a) turned 90 degrees with amino acid side chains shown in purple. The
yellow residue is V97. (c) The
he same close up but of the mutant structure with amino acid
side chains in green and the V97I mutation in yellow.
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